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The International Workshop on Meibomian Gland
Dysfunction: Report of the Diagnosis Subcommittee
Alan Tomlinson,1 Anthony J. Bron,2 Donald R. Korb,3 Shiro Amano,4 Jerry R. Paugh,5
E. Ian Pearce,1 Richard Yee,6 Norihiko Yokoi,7 Reiko Arita,8 and Murat Dogru9
Diagnostic tests of meibomian gland dysfunction (MGD)and of MGD-related disorders are based on the demonstra-
tion of abnormal anatomy and physiology of the glands and the
detection of specific pathologic events. For this reason, this
subcommittee report is divided into two sections. In part I,
those aspects of meibomian anatomy and physiology that are
relevant to currently available tests are described; a fuller
account of the anatomy and physiology is provided in the
report of the Anatomy Subcommittee of this workshop. In part
II, each test and its performance is described in detail. In part
III, the practical application of selected tests is summarized and
recommendations for future approaches are made. Additional
recommendations and a summary of pertinent literature and
concepts are presented in Appendices 1 to 17.
I. ANATOMY AND PHYSIOLOGY OF THE MEIBOMIAN
GLANDS: CLINICAL IMPLICATIONS
The superficial location of the meibomian glands in the tarsal
plates permits their anatomic features to be quantified by
meibography and confocal microscopy (Appendices 7, 8). In
normal subjects, the meibomian orifices are disposed at regular
intervals along the lid margins, just anterior to the mucocuta-
neous junction (MCJ). Biomicroscopically, they are surrounded
by a characteristic ring-shaped architecture, reflecting the con-
centric arrangement of orifice, mucosa, distal acini, fibers of
the muscle of Riolan, and the connective tissue sheath of the
glands (Fig. 1).1,2 This configuration becomes less well-circum-
scribed in old age and is destroyed in advanced MGD.3 Loss of
this architecture may be scored and is an important clinical
sign of MGD.
The lipid secretion of the meibomian glands is liquid at lid
temperature and is delivered to the skin of the lid margin as a
clear fluid termed meibum.4 Here, it forms shallow reservoirs
on the upper and lower lid margins from which the tear film
lipid layer (TFLL) is formed and replenished. The amount of
lipid present in the normal, lower lid reservoir may be gauged
by the technique of meibometry5–7 and used to infer the
content of the total lid reservoir. In meibometry, a linear
sample of meibum is blotted from the central third of the lower
lid, onto a loop of plastic tape, and the amount of lipid present
in the defined zone is gauged by the change in optical density
(Appendix 9). In normal adults, the total amount of lipid
contained in the upper and lower reservoirs has been esti-
mated to be roughly 300 g.5,8 This calculation was based on
comparisons against a standard lipid with the assumption that
the meibomian reservoir is shared equally between the upper
and lower lids. However, a comparison of basal levels on the
upper and lower lids has not yet been made. The technique
may be used to quantify meibomian gland obstruction,9 but in
the presence of MGD, the reading cannot be extrapolated to
estimate the total extent of obstruction on both lids, because of
the variability of the disease along the lid length.
As detailed in the Report on Tear Film Lipids, the meibo-
mian secretion is a complex mixture of cholesterol, wax and
cholesteryl esters, phospholipids with small amounts of trig-
lycerides and triacylglycerols, and hydrocarbons.4,10–43
The phospholipid content has been promoted as the
basis for the interaction between the TFLL and the aqueous
subphase of the tear film, necessary for tear film spread-
ing17,44; however, recent studies have reported negligible
levels of phospholipids in meibomian lipid, so that it may be
necessary to seek an alternative candidate for this interac-
tion.20,22,24 This is currently debated. The presence of hy-
drocarbons and to a lesser extent, triglycerides, has been
interpreted in part as due to contamination by sebum and
environmental chemicals.
The lipid mixture has a melting range in the region of
19.5°C to 40°C, which ensures lipid mixture fluidity at the
surface of the lid.45 The melting range of the lipid mixture also
influences its stability in the TFLL, since the temperature of the
cornea is cooler (approximately 33.5°C)46 than that of the lid
margin. This temperature difference may also be the basis of
the sustained integrity of the TFLL over a series of successive
blinks (the pleating effect, described later), a normal feature
of TFLL dynamics.47 The stability of the TFLL may be mea-
sured by static and dynamic interferometric techniques (see
Appendix 10).
The manner of secretion and delivery of meibum has been
examined by using meibometry to follow the recovery of lipid
on the lower lid reservoir after total removal of lipid from the
upper and lower lid margins with organic solvents.5 In normal
adults undergoing surgery under general anesthesia, partial
recovery occurred over periods of 3 to 40 minutes, indicating
that secretion and delivery continues in the absence of blink-
ing. Various studies have shown that, from time to time, ali-
quots of meibum are also jetted directly from some glands into
From the 1Department of Vision Sciences, Glasgow Caledonian
University, Glasgow, Scotland, United Kingdom; the 2Nuffield Labora-
tory of Ophthalmology, University of Oxford, Oxford, United King-
dom; 3Korb and Associates, Boston, Massachusetts; the 4Department of
Ophthalmology, University of Tokyo Graduate School of Medicine,
Tokyo, Japan; the 5Southern California College of Optometry, Fuller-
ton, California; 6Private Practice, Houston, Texas; the 7Department
of Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto,
Japan; the 8Department of Ophthalmology, Itoh Clinic, Saitama, Japan;
and 9Keio University School of Medicine, Tokyo, Japan.
Supported by the Tear Film and Ocular Surface Society (TFOS;
http://www.tearfilm.org); individual author support is listed in the
Appendix of the Introduction.
Submitted for publication December 6, 2010; accepted March 23,
2011.
Disclosure: Each Workshop Participant’s disclosure data can be
found in the Appendix of the Introduction.
Corresponding author: Kelly K. Nichols, College of Optometry,
338 W. 10th Avenue, Ohio State University, Columbus, OH 43210-
1280; knichols@optometry.osu.edu.
Special Issue
DOI:10.1167/iovs.10-6997f
Investigative Ophthalmology & Visual Science, Special Issue 2011, Vol. 52, No. 42006
Copyright 2011 The Association for Research in Vision and Ophthalmology, Inc.
the TFLL,6,27,48 and on this basis, it is generally accepted that
blinking plays a role in the delivery of meibomian lipid to the
TFLL.
Recent studies have followed the secretory recovery of
single meibomian glands after drainage by compression.49,50 In
these studies, a standardized device was used to apply a stan-
dard force to individual glands located at the center of the
lower lid, to drain them of their meibomian lipid. The glands
selected for study in 12 subjects aged 18 to 25 years, were
optimally secreting in the sense that expression could be ini-
tiated within 2 seconds of the application of pressure. The
mean time to effect drainage, was 12.1  3.5 seconds (range,
8–20) and the time to partial recovery of secretion was
2.2  0.5 hours. Repeat expression after partial recovery
cleared the ducts of contained secretion in about half the time
taken to drain them initially.49,50
Using meibometry, Chew5 found that the basal level of
meibomian lipid in the lower reservoir was highest within the
first hour after waking. This finding was interpreted to reflect
a damming back of secreted lipid within the ducts during
prolonged eye closure, in the absence of blinking, as in sleep,
and the release of the accumulated lipid on eye opening. The
latter hypothesis, however, neglected the potential influence
of altered lipid excretion, which has been assumed to occur
from the lid margin across the skin of the lids. It should be kept
in mind that a reduced removal of meibomian lipid during
prolonged eye closure would also lead to a rise in the recorded
basal level shortly after waking. This question should be ame-
nable to study using the compression and drainage ap-
proach.49,50
Meibomian Gland Activity
A few authors have addressed the question of gland activity in
the waking state, using the term activity to mean expressibility
of meibomian oil. Norn,51 staining with Sudan black or apply-
ing digital pressure along the full extent of the lower lid,
concluded that approximately 45% of the adult glands were
active at a given time. Here, it was assumed that, in the natural
state, those ducts receiving lipid from actively secreting glands
would be filled with liquid lipid and that would be reflected by
the ability to express their contained oil.
These findings have been supported by recent studies em-
ploying standardized meibomian gland expression. Korb and
Blackie have developed a standardized technique for meibo-
mian gland expression using a custom-made expression de-
vice49,50,52 (Appendix 6) that applies a standard force of 1.25
g/mm2 to the lid, over an area of approximately 40 mm2 (Fig. 2).
This force was chosen to approximate between that applied by
the lids to the globe during spontaneous blinking and that
applied during deliberate, forced lid closure. In studies by
Comberg and Stoewer,53 cited by Miller,54 a hard lid squeeze
results in a rise of intraocular pressure in the region of 18 to 70
mm Hg, whereas the Korb expression device raises the pres-
sure to between 30 and 40 mm Hg.49,50,52
The device achieves simultaneous expression from approx-
imately eight glands (occupying approximately one third of the
lid length, i.e., 8/24 glands). Gland expressibility is scored
according to the number of the eight glands from which a fluid
secretion can be expressed, regardless of its qualitative appear-
ance. This is the Meibomian Glands Yielding Liquid Secretion
(MGYLS) score. In a small group of normal young subjects, the
average MGYLS score for the whole lower lid was 10.6  2.6.
The range was 6 to 15.5 (25%–65% were active, presuming
there are 24 glands along the lower lid), suggesting that there is
marked variation in activity between individuals. Also, these stud-
ies have shown consistently that the nasal glands are the most
active, followed by the central glands, and finally, the temporal
glands. In the normal sample, an MGYLS score of 0 was found in
86% of the temporal parts of the lid and in 6% of the nasal parts
of the lids. The inference of these findings, already proposed by
Norn using less sophisticated methods, is that only a proportion
of the glands are actively secreting at any one time. Also, it
appears that those glands on the nasal side are considerably
more active than those on the temporal side. Pflugfelder et al.55
also evaluated meibomian gland expression in the upper lid
and described a scale in which five glands were evaluated for
expressibility, with the assumption that all glands are not
continually expressing and that a reduction in expressivity is
an indicator of disease.
In a more recent report by Blackie and Korb,56 the secre-
tory activity of individual meibomian glands was studied in
young healthy individuals without dry eye symptoms or signs.
It was found that if a meibomian gland yielded liquid secretion
at 8 AM, then, depending on its location along the lower lid,
there was a high likelihood that it would continue to provide
liquid secretion throughout a 9-hour day. For example, 70% of
the nasal glands, 30% of the central glands, and 20% of the
temporal glands provided liquid secretion throughout a 9-hour
day. If a meibomian gland did not yield liquid secretion at 8
AM, it would provide liquid secretion sporadically during the
course of the day or not at all. Assuming that meibomian glands
on the upper lid function in a similar manner, it seems that the
marginal lipid reservoirs are maintained by the activity of only
a proportion of the total number of glands. It will be of future
interest whether individual glands that are inactive at one time
become active days or weeks later. Corroboration of these
FIGURE 1. Normal lid margin, showing meibomian orifices (arrows)
and clear, expressed oil (courtesy of A. Bron).
FIGURE 2. Standardized meibomian gland expression performed at
the slit lamp using a diagnostic expression instrument (Korb and
Blackie52). See text for further details (courtesy of D. Korb). Reprinted
with permission from Korb DR, Blackie CA. Meibomian gland diagnos-
tic expressibility: correlation with dry eye symptoms and gland loca-
tion. Cornea. 2008;27(10):1142–1147.
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diurnal fluctuations in meibomian gland activity may lead to
their use in future MGD diagnosis.
While these observations have not yet been confirmed by
other groups, they have potentially important implications for
those tests of meibomian function that depend on determining
the expressibility of a set of glands.55 Based on the proportion
of expressible glands alone (without reference to either quality
of expressed secretion, state of the orifices or presence of local
gland dropout), it may be difficult to differentiate between
glands that are not expressible for physiological reasons or for
pathologic reasons (i.e., due to the presence of MGD). Obser-
vation of orifice disease at the slit lamp could be helpful. Also,
where an investigator selects expressibility as a measure of
disease, it may be appropriate to specify location for consis-
tency (e.g., the nasal third of the lid).
These studies also raise important questions about the tem-
poral characteristics of meibomian gland secretion. It may be
that the glands are engaged in a cycle of activity that changes
from gland to gland over time across the length of the lids. This
notion implies that each gland has periods of activity when
secretions are released, followed by periods of quiescence,
when their role is taken over by other glands. This hypothesis
would fit in with the holocrine mode of meibomian lipid
secretion. The studies cited earlier suggest that this does not
occur in the short term (i.e., over a 24-hour period), but there
may be a slower cycle in the long term, and this could be
relevant to the conduct of clinical trials.
The Tear Film Lipid Layer
The reported thickness range of the normal TFLL is approxi-
mately 20 to 160 nm57,58 and occupies the most anterior part
of the tear film where it performs a major role in reducing
evaporative water loss from the exposed surface of the eye.
The layer can be observed by interferometry in which the
predominant spectral color represents the TFLL thickness
(Fig. 3; Appendix 10). By interferometry (or by recording the
movement of particles in the film) the lipid layer can be seen
to spread upward in the upstroke of the blink and to become
comparatively stable after approximately 1 to 2 seconds.59
Owens and Phillips60,61 give a value of 1.05  0.39 seconds,
whereas Goto and Tseng,62 using a different approach, report
a value of 0.36  0.22 seconds in healthy eyes, but 3.54 1.86
seconds in eyes with lipid tear deficiency. King-Smith et al.59
show a time constant associated with exponential decay of
lipid drift in the upward direction of 0.564 second and total
upward movement of 3.23 mm. Prolongation of the lipid
spread time may be an indicator of aqueous tear deficiency, but
this has not yet been converted into a formal test for general
clinical use (Yokoi N, et al. IOVS 2010;51:ARVO E-Abstract
5201). The duration of the normal blink is approximately 200
to 300 ms.63,64 The direction of movement of the horizontal
wavefront suggests that the TFLL is delivered to the tear film
primarily from the lower reservoir. To explain the ability of the
meibomian lipid to spread over the aqueous subphase of the
tear film, it has been proposed that the TFLL has a lamellar
structure with an internal polar, phospholipid layer that
spreads over the aqueous phase of the tear film.17,44,65 As
noted earlier, in view of current reports suggesting a low
meibum phospholipid content,20 it may be necessary to seek
an alternative lipid layer structure. The more superficial lipid
layers are hypothesized to be composed of nonpolar lipids,
such as cholesterol and sterol and wax esters, which spread
over the polar phase. It should be emphasized that, when the
spread of the TFLL is observed by interferometry, it is the full
thickness of the TFLL that is visualized; the polar lipid layer,
which is postulated to run in advance of the nonpolar layer,
may be too thin to generate an interference pattern. Thinning
of the TFLL has been noted in lipid tear deficiency.66
In normal subjects, the interferometric pattern of the TFLL
is relatively constant in appearance over several blink cycles,
implying that its architecture is conserved to some extent from
blink to blink. This preservation occurs despite the expecta-
tion that, at the end of the downstroke of a complete blink, the
lid margins will be apposed and the lipid reservoirs combined.
To explain this phenomenon, it has been proposed that, over
this period of stability, the TFLL folds up concertina-wise in the
downstroke of the blink and is restored by unfolding during
the upstroke.57 However, it should be noted that subtle or
more marked changes in pattern can be observed from blink
to blink, which implies some kind of molecular reorganiza-
tion within the film, either by local movements of lipid
within the layer or an exchange across the apposed folds of
the lipid layer. At some point, after several blink cycles, an
abrupt and complete change in the interferometric pattern
occurs, implying a mixing of the TFLL with the combined
meibomian reservoirs. This results in a complete restructur-
ing of the TFLL and the cycle begins again. The stable
pattern is likely to be influenced by the temperature of the
surface of the open eye, influencing fluidity of the lipid
mixture, and by the composition of the meibomian lipid,
which will influence its melting range. The cycle of stability
is shortened in the presence of MGD, and this has been
proposed as a measure of MGD-related disease in the Dy-
namic Lipid Layer Interference Pattern (DLIP) test.67
With this background, the physiology of the meibomian
glands may be summarized as follows: The glands are under
neural and hormonal control and secrete their oil into shallow
reservoirs on the lid margins. Secretion is intrinsic to the glands
and delivery is aided by the blink. Only a fraction of the glands
are active at a given time, with the possible inference that each
gland goes through a cycle of activity followed by a period of
quiescence, when acinar stores are replenished. There is an
uneven distribution of gland activity along the length of the lid,
with the least distribution temporally and the greatest distribu-
tion nasally. During sleep, it is hypothesized that secreted oil
accumulates in the glands and that the excess is discharged on
waking, with the resumption of blinking. The marginal lipid
reservoir as well as direct expression from the meibomian
gland68 are the sources of the TFLL. At the upstroke of the
blink, lipid spreads from the lower reservoir onto the tear film
to form the TFLL, with polar lipids, or some other surfactant
component of the TFLL, interacting with the water phase of
the tear film. Once formed, the TFLL maintains relative stability
from blink to blink until it is reconstituted abruptly by a mixing
of lipid from both reservoirs with that of the TFLL, and the
cycle begins again.
FIGURE 3. Spreading of a normal tear film lipid layer image by inter-
ferometry (courtesy of N. Yokoi).
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Many details of this account have yet to be filled in, but this
summary may serve for the selection and interpretation of
diagnostic tests. Whether MGD occurs on its own, or is part of
a wider constellation of diseases, diagnosis requires that its
manifestations be distinguished from other, unrelated ocular
surface disorders.
Ocular Surface Disorders
Several symptomatic disorders affecting the conjunctiva,
cornea, and the lids may be conveniently grouped together
in the category of ocular surface disorders (OSDs).69 They
include lid and conjunctival disorders and those disorders
responsible for aqueous-deficient and evaporative dry eye.
There is a certain overlap, since a disorder in one category
may be associated with a disorder in another category. MGD
is a good example, since it may exist in its own right, give
rise to ocular surface damage, or cause evaporative dry eye.
These disorders correspond to those referred to as dysfunc-
tional tear syndrome (DTS) by Berens et al.70 In that report,
the term DTS was offered as an alternative to the term dry
eye, where DTS may be reasonably considered to describe
any cause of symptomatic ocular surface disease, including
dry eye.
In attempting to differentiate a particular disorder from
other members of this large group, diagnostic tests must
discriminate, not only between that particular disease and
the unaffected normal state, but also between that condition
and other members of the wider group of OSDs. This report
is focused on MGD, and as such a description of selected
tests of lacrimal function is given, since, in relation to the
diagnosis of dry eye, normal lacrimal function must be
demonstrated as part of the diagnostic work-up of evapora-
tive dry eye. Tests of meibomian and lacrimal function and
of evaporative water loss considered by the diagnostic
group are listed in Appendices 3 and 5 through 14.
Meibomian Gland Dysfunction
This report as a whole deals chiefly with MGD. Other dis-
eases of the meibomian glands are listed in Table 1 and are
also discussed in Report on Definition and Classification.
The term MGD has been widely used in the literature, as if
it were synonymous with posterior blepharitis, and has
been used in contrast to the term anterior blephari-
tis.1,36,71–74 However, as discussed by the Definition and
Classification Subcommittee, MGD is but one of several
causes of posterior blepharitis. Therefore, for clarity, only
the term MGD is used herein.
MGD can be an asymptomatic, subclinical condition de-
tectable only by gland expression or meibography. Alterna-
tively, it may be symptomatic and accompanied by specific
clinical signs (Table 2). It may be primary and unassociated
with other local or systemic disease, or it may be secondary
to a range of systemic disorders, in particular, some com-
mon skin diseases, such as acne rosacea, atopic dermatitis,
and seborrhea sicca and also, the cicatrizing conjunctival
disorders (trachoma, Stevens-Johnson syndrome, and ocular
pemphigoid).1,75 It may also be caused clinically by expo-
sure to drugs and toxins. There are several experimental
models for MGD.76
MGD may be focal, when it affects scattered glands, or
diffuse, when it affects all glands to some degree. Since the
natural history of MGD has not been studied, it is not known
whether focal disease is always a precursor of diffuse dis-
ease. It may also be cicatricial or noncicatricial (simple)
and inflammatory (meibomitis) or noninflammatory.
Characteristic signs of MGD include the release of cloudy
meibum or more viscous material on expression of the
glands or by an absence of expressible secretion. Occasion-
ally, the meibomian orifices may be capped by a lipid glob-
ule covered by an intact skin (meibomiana), or cap, which is
hypothesized to be oxidized lipid and epithelial material.
A diagnosis of MGD may be made by the demonstration of
a single affected gland, but clinically relevant disease is due to
the involvement of multiple glands. For this reason, diagnosis
demands both a qualitative and a quantitative approach.
MGD may be symptomatic in its own right or give rise to
symptoms through its contributions to ocular surface damage
or to dry eye. The mechanism of primary MGD is not known,
but the pathologic events of noncicatricial MGD include hy-
perkeratinization of the terminal ductules, accumulation of
cellular and lipid material within duct lumina, duct obstruc-
tion; cystic dilatation of the ducts and acini and secondary,
disuse atrophy of the meibomian acini73,77–79; and, at least in
some instances, periglandular inflammatory changes.202
The clinical features of MGD may be intrinsic when they
involve the meibomian glands alone or the lid tissues in their
immediate vicinity, or extrinsic, when they affect neighboring
lid structures. Intrinsic features include orifice plugging, duct
obstruction, and dilatation, gland atrophy and dropout and
qualitative changes in expressed secretions. Extrinsic features
represent secondary changes caused by the presence of MGD,
TABLE 1. Classification of Diseases of the Meibomian Gland
Reduced number of glands
Congenital deficiency
Replacement of glands
Distichiasis
Distichiasis lymphoedema syndrome
Metaplastic disease of the meibomian gland
Meibomian gland dysfunction
Hypersecretory*
Meibomian seborrhea
Hyposecretory†
Retinoid toxicity
Obstructive
Subclinical
Cicatricial or noncicatricial
Focal or diffuse
Primary, or secondary to:
Local disease
Anterior blepharitis;
Cicatricial conjunctivitis (e.g. Trachoma; Stevens-Johnson
syndrome, pemphigoid; acne rosacea, atopy
Chemical burns
Systemic disease
Seborrheic dermatitis
Acne rosacea
Atopy
Ichthyosis
Psoriasis
Anhydrotic ectodermal dysplasia
Ectrodactyly
Fungal disease
Turner syndrome
Toxicity
PCB exposure; retinoids
Other (ocular)
Internal hordeolum
Chalazion
Concretions
Neoplasia
* Although there is evidence for an accumulation of meibomian oil
within the glands, there is none yet for overproduction, as opposed to
excessive release on expression.
† Hypothetical: Evidence is not available for a condition of pri-
mary hyposecretion.
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but are encountered in other forms of OSD. They include lid
margin hyperemia and telangiectasia.
II. DIAGNOSIS AND QUANTIFICATION OF MGD
A. Clinical Subtypes and Associations with MGD
Clinically, MGD can be categorized into four subtypes, which
are described in detail:
1. MGD alone
Asymptomatic
Symptomatic (noncicatricial, cicatricial)
2. MGD with associated with ocular surface damage
3. MGD-related evaporative dry eye
4. MGD associated with other ocular disorders.
Characterization of these subtypes requires diagnosis and
quantification of MGD itself first, followed by the inclusion or
exclusion of other OSDs. Diagnostic tests are referred to briefly
in the following account. Details of each test are provided in
the appendices.
MGD Alone. Asymptomatic MGD (Preclinical). Although
MGD is a symptomatic disorder, it does, like other disorders,
go through an asymptomatic preclinical stage, when its pres-
ence may not be obvious to the clinical observer.49,50,80–82 At
this stage it may be diagnosed by meibomian gland expression,
with the demonstration of an altered quality of expressed
secretions and/or decreased or absent expression. With pro-
gression, MGD is likely to become symptomatic, and additional
lid margin signs (e.g., hyperemia) may be detected with the slit
lamp. At this point an MGD-related “posterior blepharitis” may
be said to be present.
Korb and Henriquez80 studied meibomian gland expressibil-
ity in patients with or without contact lens intolerance, by
using both gentle and forceful meibomian gland expression. In
TABLE 2. Grading of MGD According to Clinical Features and Gland Expression
Classification and Grading System Grade
Eyelid Margin
Thickness (measured posterior margin to the posterior lash
line)
0–5 
Rounding of posterior margin 0/1 
Irregularity; notching of margin 0/1 
Vascularity of lid margin: telangiectasia 0/1 
Lash loss 0/1 
Trichiasis or distichiasis (state) 0/1 
Malapposition 0/1 
Anterior blepharitis 0/1 
Mucocutaneous junction
Anteroplacement 0–3 
Retroplacement 0–3 
Ridging 0/1 
Mucosal Absorption 0/1 
Orifices
Upper Lid Lower Lid
Number present (central 1 cm)
Number patent (central 1 cm)
Pouting or plugging 0/1 
Narrowing 0/1 
Loss of cuffing definition 0/1 
Opaque/scarred 0/1 
Vascular invasion 0/1 
Retroplacement 0–3 
Other: (state) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Main Duct
Exposure (1  1 mm exposed; 2  1–2 mm; 3  2 mm) 0–3 
Cystoid dilatation 0–3 
Acini
Visibility (1  clusters; 2  yellow stripes; 3  not visible) 0–3 
Concretions (1  deep; 2  subepithelial; 3  extruding) 0–3 
Chalazia 0–3 
Expressed Secretions
Foam 0/1 
Volume: (score the diameter of the largest pool expressed) mm 
Quality: (0  clear; 1  cloudy; 2  granular; 3 toothpaste) 0–3 
Expressibility: (1  light; 2  moderate; 3  heavy pressure) 0–3 
Grading is performed in the grade range listed, and in cases of 0/1, 0  no/normal, and 1 
yes/abnormal. Reprinted in modified form with permission from Bron AJ, Benjamin L, Snibson GR.
Meibomian gland disease: classification and grading of lid changes. Eye. 1991;5:395–411; and Foulks G,
Bron AJ. A clinical description of meibomian gland dysfunction. Ocul Surf. 2003;1:107–126.
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the asymptomatic group, they found that gentle expression
generally released clear oil and rarely expressed inspissated
material the consistency of toothpaste. There was a higher
frequency of expressible glands in the asymptomatic group.
With forceful expression, the number of expressible glands
increased and in addition, more secretion was expressed from
individual glands. An important observation was that in some
asymptomatic subjects with apparently normal lids on simple
clinical inspection, expression yielded either a creamy or an
inspissated material from some glands, indicating the presence
of MGD. Evidence of asymptomatic MGD was reported by
Hykin et al.,83 who first documented an increase in clinical
features of MGD with increasing age, but free of lid-related
symptoms, and Mathers et al.43 also recorded meibomian gland
dropout in historically normal subjects. The preclinical stages
of MGD with apparently age-appropriate normal lid margins
may require expression or meibography for clinical diagnosis.
It will be important to identify which preclinical features
are likely to be predictive of progressive disease, as the ques-
tion arises whether early treatment might delay progression or
reverse pathologic events. Treatment for early-stage disease is
relatively simple, and there may be good reason to offer treat-
ment at an early, preclinical stage of the disease. This suggests
the need to perform meibomian gland expression to detect the
presence of asymptomatic MGD.
Symptomatic MGD. Meibomian gland dysfunction has both
subjective and objective features. Symptoms are a prominent
feature of the disease.
Symptoms of MGD. In the 1995 International Dry Eye
Workshop, symptoms were included in a list of global features
of dry eye, each of which was an essential component of the
dry eye, but did not link the association of the feature to either
aqueous-deficient or evaporative dry eye.84 Global features
included symptoms, ocular surface damage, tear instability,
and tear hyperosmolarity. This approach was reiterated in the
2007 DEWS report.85 No attempt was made to identify symp-
toms that distinguished aqueous-deficient dry eye from evapo-
rative dry eye.
MGD is a common disorder1,47,57,86–89 and is associated
with evaporative dry eye. It has also been suggested that
evaporative dry eye is the most common form of dry eye
disease (Castillanos E, et al. IOVS 2008;49:ARVO E-Abstract
2371), although the evidence is not strong. MGD is a symp-
tomatic disorder in its own right, with symptoms generated by
the lid disease and associated ocular surface consequences.
Where MGD occurs as the basis of evaporative dry eye, it must
be asked whether the associated symptoms are distinct from
those of the dry eye itself. However, current dry eye symptom
questionnaires are not designed either to distinguish the symp-
toms of MGD from those of dry eye (e.g., in a separate domain)
or to differentiate between aqueous-deficient and evaporative
dry eye (Appendix 1). This deficiency should be remedied, and
it is possible that questions could be identified that would
characterize MGD and distinguish it from aqueous-deficient dry
eye.
While MGD is a symptomatic disease of the lids, distinct
from MGD-based evaporative dry eye, the diagnostic watershed
between them has not been explored. Nonetheless, in those
reported studies in which evaporation rates have been com-
pared between normal subjects who lack features of ocular
surface disease and symptomatic patients with MGD,89–92 it
may be presumed that MGD patients whose evaporative rates
fell within the normal range (i.e., below the cutoff for evapo-
rative dry eye) may represent patients with symptomatic MGD
alone or MGD-associated ocular surface disease. The evidence
from recent meta-analyses of dry eye disease in which evapo-
ration (and tear turnover rate) was considered in groups sub-
divided by phenotypes of evaporative dry eye and aqueous-
deficient dry eye suggest a generally mixed etiology for both.93
Individuals with a “pure” MGD phenotype represent an inter-
esting group for further study, with the purpose of identifying
an MGD-specific symptom set. It would be of particular inter-
est to discriminate MGD from anterior blepharitis, another
cause of lid-related symptoms. At the present time, no coherent
effort has been made to identify symptoms that are specific to
MGD itself.
With the use of currently available symptom questionnaires,
one issue that arises is whether pure MGD, in the absence of
dry eye, may masquerade as dry eye and therefore decrease the
specificity of the test, when used as the sole identifier in dry
eye diagnosis. A false-positive patient may be one with MGD,
symptoms of discomfort, ocular surface staining, altered tear
film lipid layer indices, but no tear hyperosmolarity. One hope
would be that an MGD domain, consisting of a small number of
selected questions, could be added to an existing question-
naire, which would allow the diagnosis of MGD (or at least of
“blepharitis”) as a contributor to symptoms. An alternate hy-
pothesis is that it is impossible to differentiate MGD from other
ocular surface diseases on the basis of survey data alone; and
therefore, combinations of subjective and objective measures
may be necessary to fully differentiate the disease.
Some symptomatic features that might be anticipated to
characterize MGD include personal habits related to the con-
dition, such as lid rubbing to relieve itching and irritation;
morphologic features, such as visible lid margin changes (e.g.,
redness and swelling) in the absence of crusts or flakes; and the
presence of sensory symptoms referable to the lid margins
(itching, irritation, and soreness).
Clinical signs of MGD. The key signs of MGD are as follows:
meibomian gland dropout, altered meibomian gland secretion,
and changes in lid morphology. Each is described in turn,
including existing grading schemes for each parameter.
Meibomian gland dropout. Meibomian gland dropout re-
fers to the loss of acinar tissue detected by meibography43,94
(Figs. 4, 5). It implies the partial or total loss of acinar tissue.
In the original technique, the meibomian glands are ob-
served in silhouette, by transillumination through the
everted lids. The light source is applied to the skin side of the
lid, and the disposition of the glands is viewed and recorded
from the everted mucosal side. The detailed architecture of the
glands is seen well in younger people, but becomes less well
demarcated with age. The scope of this technique has been
greatly increased by the introduction of noninvasive meibog-
raphy in which the glands are documented, after eversion of
the lids, by infrared photography79 (Fig. 4; Appendices 7, 8).
FIGURE 4. Normal meibomian glands of a 38-year-old woman, viewed
by infrared meibography shows scattered gland absence or irregularity
(courtesy of R. Arita).
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Meibomian gland dropout increases with age in normal
subjects,43 not necessarily in response to the presence of
obstructive MGD. Obata has suggested that gland dropout also
occurs as an age-related atrophic process.78 It is hypothesized
that measurable dropout is a feature of MGD and increases
with MGD severity. Loss may be proximal (at the attached
border of the lid), central, or distal (at the free margin of the
lid) or may involve the whole gland. Extensive dropout is
associated with increasing evaporative water loss from the
eye.86,87,90 It will be important in the future to identify
whether total loss of meibomian gland mass and/or number of
affected glands and/or site of dropout (e.g., proximal versus
distal) has the greatest effect on the other meibomian indices,
including clinical lid characteristics, size of the marginal lipid
reservoir, spread and integrity of the lipid film, lipid composi-
tion, and the evaporation rate. No study to correlate the loca-
tion of dropout with the presence of plugging or the express-
ibility or quality of expressed lipid has yet been conducted. It
could be anticipated that distal dropout, close to the orifices,
would have the most profound functional effect and may
correlate most closely with a diagnosis of MGD. It is also
unclear whether lipid composition would be altered in the
gland with partial dropout.
Altered meibomian gland secretion: In young normal sub-
jects, digital pressure applied to the tarsal plate expresses
meiboian secretions resident in the ducts and possibly in prox-
imal acini, as a pool of clear oil. The secretion is also referred
to as meibum.4 In MGD both the quality and the expressibility
of the expressed material is altered. This material, which is
made up of a mixture of altered secretions and keratinized
epithelial debris,95 is also referred to as meibomian excreta. It
must be recognized that expressibility and secretory activity
are not the same; it is merely assumed that where meibomian
oil is freely expressible, secretion is “normal.”
In MGD, the quality of expressed lipid varies in appearance
from a clear fluid, to a cloudy fluid, to a viscous fluid containing
particulate matter and a densely opaque, inspissated, tooth-
paste-like material (Figs. 6–8). These qualities have been incor-
porated into various grading schemes.75,96,97 Alternatively, the
expressibility of glands during digital expression has been
graded55,87,98 and expressibility from single or multiple glands,
during the application of a standardized force, has also been
measured by Korb and Blackie49,50,52 (Appendix 6).
Changes in lid morphology. Several additional morpho-
logic features occur and have been incorporated into grading
schemes. These are summarized below and in Appendix 5.
Plugging of the meibomian orifices. The meibomian ori-
fices may exhibit elevations above the surface level of the lid,
referred to as plugging or pouting, which are due to obstruc-
tion of the terminal ducts and extrusion of a mixture of mei-
bomian lipid and keratinized cell debris (meibomian excreta;
Fig. 9). This is a pathognomonic clinical sign of MGD.
The meibomian orifices and the mucocutaneous junction.
Further important changes occur, affecting the location of the
meibomian orifices in relation to the MCJ and the anteropos-
terior position of the MCJ itself. This junction is important
because it forms the watershed between the lipid-wettable skin
of the lid margin and the water-wettable mucosa.
Noncicatricial MGD, previously referred to as “simple
MGD,”1,75 is a form in which, initially, the orifices retain their
position anterior to the MCJ. In this situation, restoring the
meibum delivery will allow oil be taken up once again into the
TFLL.
However, as Yamaguchi et al.99 observed in studying Marx’s
line, the MCJ migrates forward with age, causing the orifices to
lie behind the junction, within the mucosa. This process has
been called conjunctivalization.36 Marx’s line is a line of con-
junctival epithelial staining directly behind the MCJ, which is
demonstrable with dyes such as rose bengal and lissamine
green.100–103 It is present in all normal lids, in both sexes, and
at all ages. Yamaguchi et al.99 demonstrated a forward move-
FIGURE 6. Meibomian gland dysfunction. Cloudy expressed meibum
(arrows) (courtesy of A. Bron).
FIGURE 5. Photographic montage of the lower lid viewed by transil-
lumination meibography. There is extensive meibomian gland dropout
in a patient with meibomian gland dysfunction (courtesy of N. Yokoi).
FIGURE 7. Meibomian gland dysfunction: expression of opaque
meibum (courtesy of D. Korb).
FIGURE 8. Meibomian gland dysfunction: strings of toothpaste-like
opaque meibum expressed in response to forceful bimanual gland
expression (courtesy of D. Korb).
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ment of the line with age, at first encroaching on isolated
meibomian orifices, then lying at the same level, and ultimately
moving anterior to the gland orifices. As Marx’s line indicates
the location of the mucocutaneous junction, this report dem-
onstrates an anterior migration of the line itself. This was found
to correlate with the presence of MGD. This aging process
contrasts with the process, which draws the orifices posteri-
orly across the MCJ and into the conjunctiva in cicatricial
disease. Both events result in the orifice location to lie behind
the MCJ, but the mechanisms are distinctly different.
With progression, noncicatricial MGD can proceed to cause
orifice stenosis or obliteration and periductal fibrosis (Fig. 10),
so that meibomian oil can no longer be expressed by tarsal
pressure. At this point, it is clinically noted that the condition
is irreversible.
Cicatricial MGD may occur as an isolated, primary condi-
tion, in combination with noncicatricial MGD, but is most
commonly found in association with the various forms of
cicatricial conjunctivitis (e.g., trachoma, erythema multiforme,
and pemphigoid). In this case, submucosal connective tissue
scarring leads to a stretching and exposure of the terminal
ducts of the glands and a thinning of the overlying conjunctival
mucosa. This is termed ductal exposure and presents as a
slightly elevated, riblike feature that is a telltale sign of the
cicatricial process (Figs. 11, 12). Also, the affected orifices may
be dragged posteriorly, across the MCJ, onto the tarsal plate,
where they are ultimately lost to view or absorbed (Fig. 13).
The affected ductules are frequently obstructed, but on occa-
sion, pressure over the glands may express clear meibomian
oil. Since affected orifices are located in the mucosa, any oil
that they may deliver is released into the aqueous phase of the
tear film and therefore is unlikely to contribute effectively to
the tear film lipid layer (TFLL). The condition should be re-
garded as both structurally and functionally irreversible. Al-
though therapy may suppress the inflammatory events, it can-
not restore anatomic relationships. In this condition too, the
MCJ may also be dragged posteriorly.
Cicatricial and noncicatricial MGD may occur together on
the same lid margin in the absence of a conjunctival scarring
disease.
Additional features of MGD include rounding, notching, dim-
pling, telangiectasia, increased vascularity of the posterior lid
margin, epithelial ridging between gland orifices (Figs. 14, 15),
loss of orifice architecture, cystoid changes in the gland, for-
mation of concretions within the acini and, possibly, the for-
mation of chalazia (Appendix 5). The natural history of these
changes and their clinical disease associations have not yet
been explored.
B. Methods of Clinical Assessment of the
Meibomian Glands: Grading Scales
Of those techniques described in the literature, the most con-
sistently reported are those that quantify gland dropout and
grade the quality or expressibility of meibum. Although the
volume of expressed secretions has been proposed as an addi-
tional gradable parameter,90 the technique is not widely rec-
ommended, as this is a measurement of volume expressed,
recorded as the diameter of expressed meibum, and is depen-
dent both on the force applied and the duration of the force.
Quantification of MGD is important, to assess its severity and
monitor the response to therapy. It is also essential for appli-
cation in clinical trials and in tracking its natural history. The
diagnostic criteria for obstructive MGD proposed by the Japa-
nese MGD Working Group can be seen in Appendix 17.
Meibomian Gland Dropout: Grading Scales.Meibomian
gland dropout implies partial or total gland loss or atrophy and
can be quantified by meiboscopy, meibography, and confocal
microscopy (Table 3).
FIGURE 9. Cicatricial meibomian gland dysfunction. Lid margin hyper-
emia with orifice opacity with plugging (arrows); (courtesy of A.
Bron).
FIGURE 10. Advanced non-cicatricial meibomian gland dysfunction:
dense orifice opacification with periductal fibrosis (courtesy of A.
Bron).
FIGURE 11. Cicatricial meibomian gland dysfunction: All meibomian
orifices open onto the marginal conjunctiva, with some exposure of
terminal ducts (arrows) (courtesy of A. Bron).
FIGURE 12. Cicatricial meibomian gland dysfunction: All meibomian
orifices open onto the hyperemic marginal conjunctiva, with some
exposure of terminal ducts (arrows) (courtesy of A. Bron).
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Meiboscopy is the quantification of meibomian gland drop-
out by using lid transillumination94 and involves clinical obser-
vation alone. Meibography is the same technique, but using
photodocumentation.104 Most current studies employ gland
photography. Meibography is useful in providing a permanent
record, which permits masking of scoring and therefore pro-
vides greater objectivity. Such records can be handled at a
reading center, to provide improved standardization in clinical
trials. The transillumination technique is relatively time-con-
suming, is challenging in patients with thickened tarsal plates,
and may have limited general use. Arita et al.3 developed a
noncontact method of meibography in which the glands of the
everted upper or lower lids are imaged from the mucosal side
with infrared photography. The technique is said to be more
rapid and less disturbing for the patient than standard transil-
lumination meibography. More recently, Matsumoto et al.79
have measured meibomian gland density per square millimeter
and the diameter of intact glands, using in vivo confocal mi-
croscopy on the everted tarsal plate (Appendix 8). Table 3
summarizes studies of gland dropout in MGD, using the meth-
ods of meiboscopy and meibography, along with confocal
microscopy.
Pflugfelder et al.55 used meiboscopy to estimate partial or
total gland loss in the nasal and temporal halves of each of lid,
using a 0 to 3 scale in which 0 was no gland dropout and 1 was
1% to 33%, 2 was 34% to 66%, and 3 was 67% dropout.
Mathers et al.96,97 used meibography to examine the frequency
and degree of MGD in patients with chronic blepharitis. The
total number of glands lost in the central portion of the lower
eyelid (of eight adjacent glands) was measured. A score of 0.5
was assigned for half gland loss. Shimazaki et al.86,87 adopted a
relatively crude scale of 0 to 2, in which 0 is no gland dropout,
1 is gland loss involving up to half of the lower lid, and 2 is
more than half the lower lid. de Paiva,106 also scoring the lower
lid, used a 0 to 4 point scale, with 0 as no dropout and 1 as
25%, 2 as 50%, 3 as 75%, and 4 as 100% dropout.
The study by Nichols et al.107 has been particularly useful in
validating the method of meibography (Table 4). Using a near
infrared transillumination and capture system, imaging approx-
imately 15 lower lid glands, the group reported the within- and
between-observer reliability of two methods of grading. Image
quality criteria were applied, and trained observers were used.
In the gestalt system, they estimated the fractional, (partial or
total) gland loss on a 1 to 4 scale, where 1 was no gland loss
and 2 was 25%, 3 was 25% to 75%, and 4 was 75% gland loss
in the image with partial glands. Alternatively, the number of
intact glands in the region of interest was counted. It can be
seen from Table 4, that for the gestalt system, using a weighted
 statistic, the method showed near perfect reliability within
observers (  0.91) and moderate reliability between observ-
ers (  0.57). For the individual gland counting system, using
the 95% limits of agreement method, reliability was judged to
be moderate within observers and fair between observers.
The two grading methods correlated highly (z  15.15, P 
0.0001). The reader should consult the original article for
details of the statistical treatment. However, overall this report
appears to establish the method of meibography as a useful
clinical tool.
Arita et al.3 quantified glands from a montage of images
(described above). The scores for the upper and lower lid were
summed to give a scale range of 0 to 6 for the two lids. The
result was termed the meiboscore.
A body of evidence is beginning to indicate that meibomian
gland dropout correlates with the clinical features of MGD,
such as altered quality of expressed secretions and the conse-
quences of gland obstruction, such as altered tear film lipid
layer stability, increased evaporative loss, and ocular surface
damage.79 The grading of dropout at baseline and subsequent
examinations may provide information about long-term pro-
gression.
Concerning the mechanism of noncicatricial MGD–related
disease, it is assumed that duct obstruction and increasing
acinar loss (particularly distal loss) results in reduced meibo-
mian lipid delivery. This effect would be measured by gland
loss from the upper and lower lids, and the combined dropout
score from the upper and lower lids would be needed to reflect
this most accurately.
Scale ranges must be considered, to demonstrate the rela-
tionship between dropout and other parameters. Currently,
there is no consensus as to the number of discrete increments
that should be used in clinical grading. Bailey et al.110 have
addressed the effects of scaling on clinical grading and have
demonstrated an improved ability to detect clinical change
when fine rather than coarse scale increments are used. This
approach has been used effectively for the grading of corneal
staining on a 0.1-step scale increment within a 0 to 4
scale111,112 and in the quantification of cataract.113 The small
increment approach could be useful if applied to meibography.
At present, sometimes for ease of performance or for oper-
ational reasons, measurements are made on a limited region of
one lid and from either the upper or lower lid alone. This may
FIGURE 13. Advanced cicatricial meibomian gland dysfunction: orifice
retroplacement and opacity (courtesy of G. Foulks).
FIGURE 14. Dimpling or notching of the posterior lid margin due to
tissue absorption in the region of the orifices (courtesy of J. Shimazaki).
FIGURE 15. Advanced meibomian gland dysfunction: epithelial ridg-
ing extending between opacified meibomian gland orifices (courtesy
of A. Bron).
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be because it is convenient to perform expression on one set
of lids and meibography on the other. In a recent study of
meibomian gland function in blepharitis, a high correlation
between measures, including gland dropout, was found be-
tween the upper and lower lids, with the lower lid offering the
most effective single measure.114 However, in a disease that
can involve a focal portion of the lid, such measurements
cannot reliably reflect events affecting both lids of both eyes.
There is a need to develop approaches that can assess the full
extent of each tarsal plate, to produce an aggregate score.
Noncontact meibography and confocal microscopy appear
promising from this point of view.
Meibography is attractive because it offers a permanent
record and permits masking of scoring. In the future, for
clinical trials, it is likely that digital imaging techniques will be
developed that will document gland dropout more accurately
and permit a focus of attention on the terminal ductule, a
region of strategic importance.
Meibomian Gland Expression: Grading Scales. Meibo-
mian gland expression is used in diagnosis and to obtain mei-
bomian samples for lipid analysis (Appendix 6; Table 5). It is
common to express the glands by applying digital pressure
through the substance of the lids, but methods to standardize
the application of force have also been developed. When the
lids are normal, light expression may be expected to expel
secretion contained in the ducts. It is possible that heavy
expression releases presecretory lipids from the acini. Heavy
expression is necessary to express the thicker grades of
TABLE 3. Techniques for Imaging the Meibomian Glands
Technique Lid Region Grading Scheme Reference
Meiboscopy LL 0  no dropout Pflugfelder et al.55
1  33%
2  34%–66%
3  67
Percent of partial or total gland dropout
Separate measurement over the nasal and temporal
halves of the lower lid
Meibography (contact;
retro-illumination)
LL Total number of glands lost of eight central of the
lower lid. Half gland loss was given a grade of 0.5
Mathers et al.96,97
1  normal Jester et al.105
2  gland visible w/decreased absorption
3  acini atrophic; duct visible
4  no structures visible
LL 0  no dropout Shimazaki et al.86,87
1  50% dropout
2  51% dropout
LL Dropout: (nasal half, lower eyelid) de Paiva et al.106
0  no dropout Composite score with lids signs
and expressibility (0–11)
1  25%
2  50%
3  75%
4  100%
LL  15 glands Gestalt method: Nichols et al.107
1  no partial glands (PGs)
2  25% PGs
3  25%–75% PGs
4  75% PGs
Noncontact LL and UL 0  no loss, Arita et al.3
1  gland loss 33% of total area
2  loss, 33%–67%
3  67% loss
Scores of upper and lower lid summed
Scale range 0–6
Confocal microscopy LL and/or UL Acinar density: number of glands//mm2 Matsumoto et al.79
(based on a 400  400 micrometer field) mean
acinar diameter
LL, lower lid; UL, upper lid.
TABLE 4. Validation of Meibography107
Test Reliability
Gestalt method: Simple  Weighted 
Within observer   0.78, 95% CI  0.71–0.85   0.91, 95% CI  0.88–0.95
Between observer   0.38, 95% CI  0.30–0.46   0.57, 95% CI  0.47–0.85
Intact gland counting 95% limits of agreement
Within observer Moderate: 2.84–2.76 glands
Between observer Fair: 4.46–5.98 glands
 statistic scale: 0.00 poor reliability; 0.00–0.20, slight reliability; 0.21–0.4.0, fair reliability; 0.41–
0.60, moderate reliability; 0.61–0.80 substantial reliability; and 0.80 near perfect reliability.
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meibum associated with MGD or may be necessary therapeu-
tically in the treatment of MGD. Expressibility is sometimes
equated with functionality of the meibomian glands and they
are likely to be closely related, but expression is not in itself a
measurement of secretory activity, although it could be con-
sidered a surrogate measure of secretion.
In MGD, the quality of expressed oil varies in appearance
between that of a cloudy fluid, a viscous fluid containing
particulate matter and a densely opaque, toothpaste-like mate-
rial. These qualities have been incorporated into various ordi-
nal grading schemes75,96,97 (Table 5). The scores in these
four-point systems are 0, clear (normal); 1, cloudy; 2, cloudy
with particles; and 3, inspissated (like toothpaste).75 Similarly,
in the Mathers scheme, 1 is clear, 2 and 3 are liquid but of
decreasing transparency, and 4 is like toothpaste). When the
expression of a fixed number of glands is assessed, there are
two ways of generating a score. One way is to record only the
highest grade encountered from any of the expressed glands.
In this case, for a single zone, the score range is 0 to 3. The
other is to record the sum of scores for each gland expressed,
to achieve a composite score. If eight glands are expressed,
then the score range is 0  (8  3)  24. This approach is
generally preferred and is recommended by this committee.
However, a small caveat is that in long-term studies, inexpress-
ibility encountered in normal lids is also a sign of total obstruc-
tion; an increase in the number of pathologically inexpressible
glands with disease progression, would, paradoxically, lead to
a fall in total score.
TABLE 5. Grading Meibomian Gland Expression
Technique Study Details Lid Region Grading Scheme Reference
Meibum Characteristics
Firm digital pressure Volume of expressed meibum Central eight glands
of lower eyelid
0  Normal volume. Just covers orifice
1  increased to 2 to 3 times normal
2  increased more than 3 times
3  increased more than 10 times
Mathers et al.96,97
Firm digital pressure Viscosity of expressed meibum Central eight glands
of lower eyelid
1  normal, clear, may have a few particles
2  opaque with normal viscosity
3  opaque with increased viscosity
4  severe thickening (toothpaste)
Mathers et al.96,97
Firm digital pressure Volume and viscosity of
expresssed meibum
Clinic-based; referred for dry
eye or blepharitis
n  513 total;
n  76 normal women
(used to define aqueous
deficiency)
Central eight glands
of lower eyelid
Obstructive:
Viscosity  3 (1, clear; 2, slightly
opaque; 3, thick, opaque; 4,
toothpaste
Avg. lipid volume: 0.3 mm (diameter of
expressed lipid in millimeters)
Dropout: 0 (presumably examined
central eight glands; includes 1/2 and
whole glands)
Seborrheic:
Viscosity: no criteria
Avg. lipid volume: 0.7 mm
Mathers et al.96,97
Mathers and
Billborough108
Meibum Quality and Expressibility
Firm digital pressure Quality of meibum Number of glands
not stated
UL or LL
0  clear fluid
1  cloudy fluid
2  cloudy particulate fluid
3  inspissated, like toothpaste
Bron et al.75
Firm digital pressure Expressility of meibum from
five glands
UL or LL 0  all glands expressible
1  3–4 glands expressible
2  1–2 glands expressible
3  no glands expressible
Pflugfelder et al.55
Standardized application
of pressure
Expression applied to a set of
about eight glands
Nasal, central and
temporal lid
The MGYLS score is the number of
Meibomian Glands out of 8, Yielding
Liquid Secretion
Korb and Blackie52
Blackie and Korb81
Meibum Expressibility
Variable digital pressure Gentle or forceful expression LL Analysis of expressed secretion Henriquez and Korb98
Variable digital pressure Expressibility of meibum LL 0  clear meibum, easily expressed Shimazaki et al.86,87
1  cloudy meibum, easily expressed
2  cloudy meibum expressed with
moderate pressure
3  meibum not expressible, even with
hard pressure
Variable digital pressure
using the Shimazaki
schema
Measurement of lid
morphology, expression
and meibography
See grading box Lid margin:
Irregular
Vascular engorgement
Plugged orifices
Displacement of MCJ, score “1” for each
present
Arita et al.109
Clinic based
n  53 obstructive MGD
subjects
n  60 age-matched
controls
Expressed meibum (upper eyelid):
0  clear, easily expressed
1  cloudy, mild pressure
2  cloudy,  moderate pressure
3  meibum not expressed, with hard
pressure
Meibography: upper and lower eyelids,
meiboscore summed (0, no loss; 1,
gland loss  33% of total area; 2,
loss  33–67%; 3, 67% loss)
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In addition, the expressibility of glands during digital ex-
pression has been graded,55,87,98 while expressibility from sin-
gle or multiple glands, during the application of a standardized
force, has been measured by Korb and Blackie (Table 5).49,50,81
For multiple glands, the standard force is applied for 10 to 15
seconds with a specially designed instrument.52 The Shimazaki
approach grades expressibility according to the response to
different levels of digitally applied pressure and therefore
brings an additional subjective element into the grading pro-
cess. The approaches of Pflugfelder and of Korb relate to a
fixed number of expressed glands, and the latter system clearly
instructs the investigator to score only those glands that yield
a liquid secretion (the MGYLS score), regardless of its quality
(Table 5). To increase the scale range and reflect the status of
the full length of the upper and lower lids, an aggregate score
can be created from the summed expression grades from the
nasal, central, and temporal regions of each lid. As noted
earlier, even in young normal subjects, the expressibility, in
terms of the fraction of glands from which fluid meibum may be
expressed, varies for different regions of the lid and reduces
progressively from the nasal to the temporal side.49,50 However, it
may be reasonable to generate a composite score for the upper
and lower lid by summing the nasal and central scores from each
lid, not attempting to score the temporal region.
Grading Morphologic Lid Changes: Grading Scales.
The approaches to grading (Appendix 5) other morphologic
features of MGD were discussed earlier and are presented in
Table 2. Grading scales may be expanded by dividing each lid
into quarters and grading the highest level of change in each
region.75 Quantifying selected features in this way offers an
opportunity to generate an aggregate MGD score that may then
be used in conjunction with measures of gland expressibility
and dropout.1 This approach was adopted by de Paiva et al. in
a comparison of normal subjects with those who had ocular
irritation.106 An aggregate score with a scale range of 0 to 11
was created by combining a meibographic grading (see Table
2) with a grading of lid changes, as follows: Orifices: metaplasia
present is 1; absent is 0; and brush marks (linear vascular
features): present is 1, absent is 0; Expressibility using digital
pressure applied over five lower lid glands: 0 is all five glands
expressible and 1 is four, 2 is three, 3 is two, and 4 is 0 glands
expressible. Similarly, Arita et al. scored for the presence or
absence of lid abnormalities, as follows: irregularity of the lid
margin, lid margin vascular engorgement, plugging of the mei-
bomian orifices, and anterior or retroplacement of the MCJ,
giving a score of 0 to 4.
C. The Utility of Current Grading Scales
These various tests have been used to explore the prevalence
of MGD and its relation to ocular disorders. Age-related data are
available in normal subjects concerning morphologic lid
changes, lipid levels at the lid margin, meibomian gland drop-
out, and expressibility of meibomian secretion.
Mathers and et al.43,115 used meibography to examine 72
normal subjects without dry eye and found that gland dropout
remained, on average, below one gland per eight assessed, up
to about age 50 years. After that, it increased to approximately
two glands per eight assessed (25%). Similarly, using noncon-
tact meibography, Arita et al.3 found a significantly positive
correlation between the meiboscore (implying dropout) and
age (R  0.428; P  0.0001). They found meiboscores up
to about grade 1 (i.e., gland loss under a third of the total
gland area) at age 50 in normal subjects and then increasing
scores and gland dropout with advancing age.
In a study of asymptomatic, normal subjects, Hykin and
Bron,116 showed changes related to age, including increasing
lid margin telangiectasia and cutaneous hyperkeratinization,
increased narrowing and pouting (plugging) of meibomian
gland orifices, and a decreased number of expressible glands.
The quality (viscosity and degree of opacity) of expressed
secretions did not change. In contradistinction, Mathers and
Lane43 found that lipid viscosity increased with advancing age
in normal subjects, a change that was highly significant for
linear trend (P  0.0006).
Chew et al.5 used meibometry in a large sample of normal
subjects (n  421) and found increasing lid margin levels of
meibomian oil throughout life, with no differences found be-
tween the sexes after approximately age 50. These meibom-
etry results seemingly contradict the finding that meibum is
expressible from fewer orifices with advancing age.116 The
paradox could be explained by a greater meibometry pickup
from the lid margin with age.
Yamaguchi et al.99 assessed the disposition of Marx’s line in
normal subjects by using fluorescein and other dyes and the
following grading system: 0, Marx’s line runs entirely on the
conjunctival side of the meibomian orifices; 1, parts of Marx’s
line touch the meibomian orifices; 2, Marx’s line runs through
the meibomian orifices; and 3, Marx’s line lies on the skin side
of the meibomian orifices. Grading was performed in the inner,
central, and outer thirds of the lower lid, giving a range of
scores for the whole lid of 0 to 9. It was found that grading was
reasonably consistent between observers. With age, the grade
score increased, implying that Marx’s line (and the MCJ)
moved anterior with time. The authors found a positive corre-
lation between the regional meibography scores and quality of
expressed meibum score (graded on a 0 to 4 basis), and the
regional Marx’s line scores.
Several investigators (using the various methods discussed
herein) have shown decreasing functionality of the meibomian
glands with aging. Norn51 found that a maximum of approxi-
mately 14.5 lower lid glands could be expressed by digital
pressure in normal subjects at the at age of 20 years but that the
number dropped to approximately seven glands beyond the
age of 80 years. Hykin and Bron116 later confirmed these
results.
Mathers et al.96,97 reported a prevalence of MGD of 20% in
the normal population older than 20 years. In other studies the
population prevalence of MGD has been reported to range
between 3.5% and 68%. Arita et al.109 reported that positive
meiboscores develop after the age of 20 years in men and after
the age of 30 years in women. Meiboscores correlated with age
in both sexes (R  0.428: P  0.001) and there was also a
positive correlation between the lid margin score (based on a
cluster of features) and age (R  0.538: P  0.0001) and
between the meiboscore and lid margin score (R  0.289;
P  0.0001).
Several investigators have concluded that meibomian gland
dropout is a useful index of obstructive MGD.86,87,94,96,97 Us-
ing meibography, Mathers et al.96,97 found meibomian gland
dropout in 76% of their patients with chronic blepharitis. The
dropout score in their normal group was 0.18  0.1 (per eight
lower lid gland surveyed) compared to 1.97  2.1 in their
blepharitis group, which likely contained patients with non-
MGD forms of blepharitis. On the basis of a cluster analysis,
they concluded that only gland dropout was useful in classify-
ing dysfunction. Obstructive MGD was associated with a high
level of dropout (mean 3.67  1.7 glands missing per eight
glands surveyed; nearly 50%) versus normal subjects (mean
0.18  0.1 glands missing; 2.2%). This study identified a
group of patients with high levels of meibomian gland dropout,
a high level of tear osmolarity, and high Schirmer values. This
group would correspond well to that predicted by Bron
et al.117 as an example of patients with evaporative dry eye
during a phase of partial, reflex lacrimal gland compensation. A
further group of patients was identified with high levels of
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meibomian gland dropout, tear hyperosmolarity, and low
Schirmer values. This group would correspond to a more
advanced stage of evaporative dry eye, in which it is predicted
that lacrimal compensation has failed and evaporative dry eye
is accompanied by a functional, aqueous-deficient dry eye. An
average dropout of 5.5  1.3 glands (69% of eight glands)
was found in this sicca group. This contrasts with much lower
levels of gland dropout for subjects with seborrheic MGD and
those with low Schirmer scores alone. Taken together, these
results suggest that quantitative assessment of gland dropout is
a valuable indicator of obstructive MGD.
Pflugfelder et al.55 used clinical meiboscopy to assess gland
dropout in several dry eye subtypes, albeit with modest sample
sizes (n  9–11 subjects per subtype). These authors found
mean gland dropout scores (graded on a 0–3 scale based on
percentage of gland dropout) of approximately grade 2 for
inflammatory and noninflammatory MGD subjects compared to
a grade 0.5 for the controls. A significant finding in their
report was that the degree of acinar loss in inflammatory MGD
and atrophic MGD was roughly equivalent. Thus, gland drop-
out alone may not adequately discriminate these two clinical
conditions. Khanal et al.118 found gland dropout to be effective
in differentiating the evaporative dry eye subtype from those
without dry eye, but was not effective in differentiating aque-
ous-deficient dry eye.
Matsumoto et al.,79 using confocal microscopy, have shown
a decrease in meibomian gland density in MGD patients
(47.6  26.6/ mm2, compared with 101.3  33.8/ mm2 for a
control group). This group also introduced the measurement
of meibomian gland diameter as a new parameter reflecting the
health of the glands (Fig. 16). In their study, MGD was associ-
ated with an increase in residual gland width (98.2  53.3 m
in MGD and 41.6  1.9 m in controls) that was attributed to
accumulated, inspissated debris within the acini. However, an
alternative explanation may be that acinar enlargement is in
part compensatory, due to the influence of a feedback loop.
This review of the current literature suggests that quan-
tification of meibomian gland dropout provides a valuable
baseline statement about the integrity of the meibomian
glands. The dropout score appears to correlate with the
presence of MGD diagnosed by other clinical criteria and to
the effects of MGD on the surface of the eye.
MGD with Associated OSD. OSD is encountered in asso-
ciation with MGD and is found in its most advanced form in
MKC. Various etiologies have been proposed for such damage,
including the release of inflammatory mediators into the tear
film and the mechanisms of evaporative dry eye. One source of
such mediators includes the breakdown products of meibo-
mian lipid, altered by the lipases of microbial commensals. A
possible relationship has been reported between meibomitis
and phlyctenular keratitis, a keratitis that is sometimes encoun-
tered in young females. In a small group of patients with
phlyctenular keratitis, 57% of whom had a history of chalazia,
the location and severity of a meibomitis correlated well with
the severity of the corneal nodules, and there was a possible
association with specific HLA subtypes and with the presence
of Propionibacterium acnes in expressed meibum.119
Ocular surface damage may be quantified by grading
staining of the cornea and conjunctiva using selected dyes,
by immunohistochemistry or flow cytometry on impression
cytology specimens, and by the direct measurement of in-
flammatory mediators in the tears biochemically, with mul-
tiplex bead technology or using MALDI-TOF and proteomic
techniques.120 These biochemical and clinical techniques
have helped to describe the ocular surface phenotype in
MGD and other OSDs and to monitor the severity of disease
and response to treatment, but the events that they record
are not specific to MGD, and they therefore have no unique
role in its diagnosis. The precision of such tests was ad-
dressed in the 2007 DEWS Diagnosis report, and details of
test sensitivity and specificity in the diagnosis of dry eye are
summarized and incorporated both in the published tem-
plates and in additional materials available on the TFOS web
site (www.tearfilm.org), Intrinsic glandular inflammatory
events may be recorded directly by confocal microscopy
(Appendix 8).
MGD-Related Evaporative Dry Eye. In the presence of
MGD, the amount of oil delivered to the reservoir is re-
duced, as a result of meibomian obstruction or gland atro-
phy or, in the case of cicatricial MGD, because the affected
orifices are malpositioned, and the ducts are stretched and
narrowed. A combination of mechanisms may often be at
work when these forms of MGD occur together. With pro-
gression of MGD, it is assumed that a point is reached when
the amount in the reservoir, or its distribution along the lid
margins, is insufficient to maintain a normal TFLL, so that a
functionally incompetent TFLL results. It is likely that com-
positional changes in meibum contribute to this distur-
bance, too. Abnormalities of the TFLL include abnormal
(slow) spreading patterns,121 vertical interferometric pat-
terning, and reduced TFLL stability. These are accompanied
by an increased evaporative water loss (Fig. 17).
It is known that spreading of the TFLL is altered in the
higher degrees of aqueous-deficient dry eye.62,66,122 This
spreading has been attributed to thinning of the aqueous layer
of the tear film.123 In a recent publication, it was suggested that
this effect gives rise to a functional TFLL deficiency and a
consequent increased evaporative water loss.117 Thus, it is
proposed that a functional evaporative dry eye may occur in
the presence of organic aqueous-deficient dry eye. This type of
dry eye is predicted to occur in the absence of MGD, but would
be compounded by it, if present. No TFLL spreading can be
detected with a video-interferometer (DR-1; Kowa, Tokyo, Ja-
FIGURE 16. In vivo confocal microscopy of meibomian glands, show-
ing the dilatation of acinar units in a patient with obstructive meibo-
mian gland dysfunction (right) compared to that in a healthy control
(left) (courtesy of M. Dogru).
FIGURE 17. Evaporimetry (courtesy of A. Tomlinson).
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pan) in the severest form of aqueous-deficient dry eye, but
recovery can be confirmed, after punctal occlusion.66,124
MGD Associated with Other Ocular Disorders. There
have been extensive reports of the association of MGD with
other ocular and systemic disorders in the literature, including
contact lens (CL) intolerance. The level of evidence associated
with each ocular and systemic factor is discussed in detail in
the report of the Epidemiology Subcommittee and is discussed
briefly here for clinical significance.
Meibomian Keratoconjunctivitis. McCulley and Sciallis72
described a condition of tear film instability, ocular inflammation,
and ocular surface damage in a group of patients with chronic
blepharitis, which they called MKC (Table 6).72,125 In the study,
patients exhibited both anterior and posterior blepharitis and
some form of associated skin disorder. The features of MKC are
summarized in Table 6. Signs of obstructive MGDwere associated
with conjunctival injection and superficial punctate keratitis
(SPK), preferentially affecting the lower interpalpebral globe and
cornea. In all cases, MKC was associated with some form of skin
disease, such as seborrhea sicca, (11.5%), acne rosacea (34.6%), or
seborrheic dermatitis, on its own (38.5%) or in combination with
atopy (15.4%).
MGD and CL Wear. MGD is frequently associated with CL
intolerance,80,98 and there are several clinical reports of an
association between MGD and giant papillary conjunctivitis
(GPC). Mathers and Billborough108 found significantly more gland
dropout and greater viscosity of expressed secretions in CL wear-
ers with GPC than without GPC, whereas Martin et al.126 found
that the severity of GPC correlated with the severity of the MGD
in a consecutive series of GPC patients. Although attention has
been focused on the hypothesized role of MGD in CL intolerance
and GPC, it is also possible that the conjunctivitis initiates changes
in the meibomian gland by the release of inflammatory mediators.
Ong and Larke127 found an increase in the frequency of MGD
after 6 months of CL wear, and Arita et al.109 recently reported
that CL wear is associated with a decrease in the number of
functional meibomian glands, proportional to the duration of CL
wear. Further research is necessary to determine the role of CL
wear in the development of and/or progression of MGD.
Mixed Anterior Blepharitis and MGD. Mixed anterior
blepharitis associated with MGD is not uncommon and is
often encountered clinically in seborrheic blepharitis,125 in
atopic blepharitis,128,129 and as a specific complication of
systemic retinoid therapy.130
Documenting MGD in Different Clinical Situations.
Quantification of MGD is important for diagnosis and treat-
ment, but is also required in other clinical circumstances.
Recruitment of Patients for Clinical Trials. Dry Eye.
Certain considerations apply in the recruitment of patients for
trials of drugs to treat aqueous-deficient dry eye. Since exten-
sive MGD may be associated with dry eye, there may be
reasons to exclude patients exhibiting the higher grades of
MGD, which may exacerbate the dry eye and influence inter-
pretation of drug efficacy. On the other hand, particularly in
recruitment of patients with severe dry eye, it is unrealistic to
exclude all patients with MGD. A compromise is to permit
recruitment of patients with a low degree of MGD, based on
meibum quality or expressibility. The MGD grade can be used
for stratification in data analysis.
MGD. In clinical trials of drugs for the treatment of MGD or
of MGD-related dry eye, a higher grade of MGD would be
required at recruitment in order to demonstrate efficacy and
permit responder analyses. The MGD grade, determined by
one of the methods described above, would be recorded over
the course of the study. An assessment of functionality, such as
by the MGYLS score, would be an important inclusion.52 Mea-
surement of gland dropout offers an objective way to stratify
the baseline severity of the MGD. A detailed summary of exist-
ing trials is presented in the report of the Clinical Trials Sub-
committee.
Monitoring for MGD as an Adverse Event. MGD is a side-
effect of systemic retinoid therapy, used in the treatment of
acne vulgaris.97,131 In studies of the evolution of such changes
it is necessary to recruit subjects with a low degree of MGD, in
order that the development of pathological changes may be
monitored carefully and detected quickly. This implies recruit-
ing a relatively young, adult population and confining assess-
ments to the nasal and possibly the central thirds of the lower
lids, where normally, the percentage of active glands is rela-
tively high.52
Natural History of MGD. While the natural history of MGD
is not yet known, clinicians and researchers have the tools to
address this in the future. Such studies would allow the evo-
lution of primary MGD to be elucidated and could identify the
chain of events leading to secondary forms of MGD.
III. A PRACTICAL APPROACH TO THE DIAGNOSIS OF
MGD AND MGD-RELATED DISEASES
Standardization and accessibility are the keys to successfully
performing any test. Standardization can be achieved in any
clinic by performing examinations within a standard envi-
ronment and ensuring, when auxiliary staff are involved,
that the staff are well trained. The diagnosis of MGD,
whether in isolation or associated with ocular surface dam-
age or dry eye, should be viewed in the context of diagnos-
ing any ocular surface disease, and tests should be per-
formed in an order that minimizes the extent to which one
test influences the tests that follow.
The evidence base of tests used to define dry eye and its
subtypes is summarized in Table 7. The effectiveness of these
tests varies between 50% and 96%. However, the quality of evi-
dence on which these statistics is based varies from study to
study, dependent on the initial quality of the investigator’s defini-
tion of the condition, the presence of selection bias in the study
design, and the size and sample of the population studied. It can
be seen from examining Table 7 that if a 70% level of sensitivity
and specificity is accepted as appropriate for an effective test,
several clinical and laboratory-based tests are effective in differen-
tiating the normal from a generic dry eye. On the basis of the
evidence in Table 7, however, when evaporation rate is used as
the gold standard, only two types of tests, tear secretionmeasured
by fluorophotometry and the fluorescein clearance rate, are
able to differentiate evaporative- from aqueous-deficient dry
TABLE 6. Features of Meibomian Keratoconjunctivitis72
Anterior blepharitis Ocular surface damage
Crusting (61%) SPK (100%)
Scales Rose bengal staining (100%)
Lash loss (58%)
Lid margin irregularity (46%)
Posterior blepharitis Ocular inflammation
Oil stagnation (100%) Bulbar injection (100%)
Orifice abnormalities (23–53%) Tarsal papillary change (100%)
Meibomian foam (62%)
Reduced tear secretion General signs
Schirmer test 10 mm (35%) Concretions
An excess of tear debris
Tear film instability Clinical associations
Reduced BUT (100%) Seborrhea sicca; seborrheic
dermatitis with or without
atopy; acne rosacea
SPK, superficial punctate keratitis; BUT, break-up time.
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eye, at the second stage of diagnosis. However, a diagnosis
of evaporative dry eye can be reinforced by positive findings
from meibography, meibometry, scoring the functional se-
verity of the MGD, and measures of TFLL dynamics.
With this background in mind, a series of recommended
tests to be used in the diagnosis of MGD and in MGD-related
disorders, including evaporative dry eye, is presented as fol-
lows (Table 8).
1. Tests for the Diagnosis of MGD
a. In asymptomatic adults it is appropriate to include
gland expression (e.g., by the application of moderate
digital pressure to the central lower lid) to the routine
work-up of the patient, to detect asymptomatic, nonob-
vious MGD.
i. A diagnosis of MGD may require that the patient be
further assessed for ocular surface damage and dry
eye, by using appropriate diagnostic techniques.
ii. In patients with ocular surface symptoms or morpho-
logic lid signs of MGD (e.g., orifice plugging and other
orifice or lid margin signs), meibomian gland function-
ality should be assessed by digital pressure over the
central (nasal) third of the lower/upper lids, to deter-
TABLE 7. Diagnostic Efficacy of Tests for Evaporative and Aqueous-Deficient Dry Eye
Test Measure
Normals vs. Dry Eye
(Sens %/Spec %)
Normals vs. EDE
(Sens %/Spec %)
EDE vs. ADDE
(Sens %/Spec %)
Symptom questions DE 14.5 (82/36; vs. RB, SCH,
TBUT); McMonnies132
DE 15; OSDI; (80/79 vs.
Lissamine, Sch, Symp) (60/83,
Dr. diagnosis); Johnson and
Murphy133
Tear stability FBUT 10 seconds (82/86);
Mengher et al.134
Tear secretion: Schirmer I,
Schirmer II
5.5 mm/5 min (85/83); Khanal
et al.92
Index of tear volume, PRT PRT 12 mm (56/69); Sakamoto
et al.135
PRT 20 mm (86/83); Patel
et al.136
Ocular surface damage RB Stain 3.5; van Bijsterveld137
RB Stain 4 (95% vs. 96%)
(63/84); Vitali et al.138
Lid (meibomian morphology) NA
Meibomian gland expression Expression grade 1.0*
Expressibility/volume/quality 86/73
Meibography EDE  3 (83.0/90.0); Arita et al.3
Confocal acinar unit density/
diameter
Unit density 70/mm; Kobayashi
et al.139; Matsumoto et al.140
(81/8)
Long diameter 65 m (90/81)
Short diameter 25 m (86/96)
Meibometry NA
Interferometry NA
Evaporation rate DE 22 (51.1/89.9); Tomlinson
et al.93
EDE 22.3 (61.2/90.6) EDE 27.5 (45.5/79.8)
Meibomian physicochemistry
Tear secretion: fluorometry,
fluorescein clearance
DE 12.9 (74.5/73.6); Tomlinson
et al.93
EDE 15.1 (80.2/58.7) ADDE 9.6 (69.5/96.8)
Tear volume: fluorimetry NA
Tear meniscus height/radius/
volume
DE 0.25 (74.5/73.6)-R; Yokoi
and Komuro124
DE 0.18 (72.8/66.6)-TMH; Farrell
et al.141
DE 9.6 (93.3/66.7); Mainstone
et al.142
Tear osmolarity DE 31694 (69%/92.8%);
Tomlinson et al.93
EDE 315 (73%/72%); Khanal
et al.118
ADDE 325 (60%/39%);
Khanal et al.118
Tear dynamics/indices/evap/total
flow
DE 15 (NA); Tomlinson et al.93 EDE 15; Tomlinson et al.93 (na) EDE NA (NA)
Tear dynamics/indices/
evaporation/TTR
DE 20 (NA); Tomlinson et al.93 EDE 20 (NA); Tomlinson et al.93 EDE NA (NA)
Tear dynamics/indices/TFI DE 96; Xu et al.143 NA
DE 240 (64.7/60) (83%/40%);
McCann et al.144
The sensitivity and specificity of tests discriminating normals from dry eye and its subtypes are reported. DE, dry eye; EDE, evaporative dry
eye; ADDE, aqueous-deficient dry eye; TFI, tear function index; FBUT, fluorescein break-up time; PRT, phenol red thread; RB, rose bengal; SCH,
Schirmer; TBUT, tear breakup time; TTR, tear turnover rate; SENS, sensitivity; SPEC, specificity.
* McCann LC, et al. IOVS 2008;49:ARVO E-Abstract 1532.
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mine the extent and severity of the MGD (expressibility
and secretion quality). This procedure should be per-
formed using moderate digital pressure or a standard-
ized technique, in the manner outlined in the previous
sections. The patient should be further assessed for
evidence of ocular surface damage and dry eye.
2. Tests for the Diagnosis of MGD-Related Dry Eye
The Committee recommends a two-tiered approach:
a. The first step is one in which normal subjects are dis-
criminated from patients with dry eye of any type (ge-
neric dry eye).
b. The second step involves the differential diagnosis of MGD-
related evaporative dry eye from aqueous-deficient dry eye.
Two approaches are proposed: one suitable for practitioners
working in a general clinic and the other for investigators
working in specialized units. The evidence base of the tests
proposed varies according to the clinical setting needs.
A. Diagnosis of MGD-Related Disease within a
General Clinic
A suitable sequence of tests to perform in a general clinic, in
patients presenting with symptoms of ocular surface disease is
as follows:
1. Administration of a symptom questionnaire.
2. Measurement of the blink rate and calculation the blink
interval (BI).
3. Measurement of lower tear meniscus height.
4. Measurement of tear osmolarity (if available).
5. Instillation of fluorescein and measurement of the tear film
breakup time (TFBUT). Measurement is facilitated by viewing
with a blue exciter filter and a yellow barrier filter. The diag-
nostic cutoff value for dry eye will be influenced by the volume
instilled. The Ocular Protection Index145 can be calculated as
the ratio of TFBUT/BI (blink interval). A value of 1 is patho-
logic and implies that tear breakup is occurring in the waking
state. The lower the value the greater the degree of tear film
instability.
6. Immediately after measurement of the TFBUT, fluorescein
staining can be graded on both the exposed cornea and
conjunctiva. When a yellow barrier filter has not been used,
it will be necessary to grade conjunctival staining indepen-
dently by using lissamine green. This grading may be per-
formed after the Schirmer test.
7. Schirmer test or alternate (phenol red thread test).
A positive result (abnormal) from tests described in 1, 4, 5,
and 6 provides partial evidence of the presence of generic
dry eye, without specifying whether it is aqueous-deficient
or evaporative. Evidence of aqueous-deficient dry eye may
be obtained by measuring tear flow or an assessment of
aqueous volume on the basis of tear meniscus height or
Schirmer test.
8. If MGD has not been characterized (symptomatic/ asymp-
tomatic) at a previous visit, then it can be assessed at the end
of this sequence as follows:
a. Quantification of morphologic lid features.
b. Expression: quantification of meibum expressibility/quality.
c. Meibography: quantification of dropout.
If testing suggest the diagnosis of a generic dry eye and tests
of tear flow and volume are normal, then evaporative dry eye
is implied, and quantification of MGD will indicate the meibo-
mian gland’s contribution.
This test sequence also permits a diagnosis of symptomatic
MGD, with or without ocular surface staining and with or
without dry eye, to be made. The graded scores for each test
can be used to monitor the disease during treatment.
TABLE 8. Specialized and Nonspecialized Tests for MGD and MGD-Related Disease
Testing Category Specific Test(s) Tests for a General Clinic Tests for a Specialized Unit
Symptoms Questionnaires McMonnies; Schein; OSDI; DEQ;
OCI; SPEED etc.
McMonnies; Schein; OSDI; DEQ; OCI; SPEED
etc.
Signs
Meibomian function Lid morphology Slit-lamp microscopy Slit lamp microscopy Confocal microscopy
Meibomian gland mass — Meibography
Gland expressibility Slit-lamp microscopy Slit lamp microscopy
Expressed oil: quality
Expressed oil: volume
Lid margin reservoir — Meibometry
Tear Film Lipid Layer
Thickness Interferometry Interferometry
Spread time Slit-lamp Slit-lamp
Spread rate — Video interferometry
Evaporation Evaporimetry — Evaporimetry
Tears
Osmolarity Osmolarity TearLab device, other TearLab device, other
Stability Tear film TFBUT; OPI TFBUT; OPI
TFLL Spread time Interferometry; spread rate; pattern
Indices of volume
and secretion
Tear secretion
Tear volume
Tear volume
Tear clearance
Schirmer 1
Not available
Meniscus height
TFI
Fluorophotometry/FCR
Volume by fluorophotometry
Meniscus radius of curvature; meniscometry
TFI
Ocular surface
inflammation
Ocular surface staining
biomarkers
Oxford scheme; NEI/Industry
scheme
Flow cytometry; bead arrays; microarrays; mass
spectrometry: cytokines and other
mediators; interleukins; MMPs
Tests of meibomian gland function are presented first followed by those for related disorders such as dry eye. See text for a recommended
sequence of performance. DEQ, Dry Eye Questionnaire; FCR, fluorescein clearance rate; MMPs, matrix metalloproteinases; OCI, Ocular Comfort
Index; OPI, Ocular Protection Index; OSDI, Ocular Surface Disease Index; SPEED, Standard Patient Evaluation of Eye Dryness; TFBUT, tear film
breakup time; TFI, tear film index; TFLL, tear film lipid layer.
IOVS, Special Issue 2011, Vol. 52, No. 4 Diagnosis 2021
B. Diagnosis of MGD-Related Disease within a
Specialized Unit
An “ideal” or comprehensive test series is proposed for corneal
specialists or for investigators engaged in clinical trials, in which
they have access to a wider range of diagnostic equipment. Some
of the tests listed are alternatives. It is suggested again that the
diagnosis be made in two steps: First, diagnose generic dry eye
and then subtype it with the grade of MGD.
This test series consists of a symptom assessment (Ap-
pendix 1; e.g., the OSDI,146 DEQ,147), a measure of tear
osmolarity (Appendix 15), a tear secretion test (fluoropho-
tometry or fluorescein clearance rate; Appendix 13), a mea-
sure of the volume of the tears in the eye (by fluorophotom-
etry and meniscometry; Appendix 14), a stability test (the
TFBUT or noninvasive TBUT, Appendix 2; or interferometry,
Appendix 10), and a measurement of tear evaporation (by
evaporimetry, Appendix 11). Tests of ocular surface dam-
age, such as corneal and conjunctival staining (Appendix 4),
are also included in the test series (Table 9). Tests of inflam-
matory mediators and the presence of inflammatory cell
markers and other proteomic and lipidomic mass spectrom-
etry analyses (Appendix 12) can also be assessed to provide
information regarding overall ocular surface inflammatory
status, although the link to MGD specifically is not known at
this time. Specific measures of tear production (Appendix 3)
for the diagnosis of aqueous-deficient dry eye are also rec-
ommended.
A Severity Scale for MGD and MGD-Related
Disease, Including Dry Eye
It is critical to understand the severity of any disease to
assess its burden to the patient, the efficacy of therapy, and
the prognostic implications (Appendices 5–7). Assigning
severity levels to a disease is difficult, because the various
elements that comprise the disease complex are of different
weight and may not move in parallel as the disease pro-
gresses. The committee acknowledges that information of
this kind is not yet available to inform the development of a
severity rating for MGD and related disease. However, it was
considered to be important to offer a provisional framework
that could be assessed in the future as described below.
In the preamble to this section, we suggested that MGD may
be a symptomatic disorder in its own right, a disorder that causes
ocular surface damage and one that causes evaporative dry eye,
which in turn may cause surface damage. Because these disease
components may progress at different rates, separate severity
levels have been generated for MGD and for MGD-associated
disorders, using symptoms as a bridge between the two.
Severity levels for the parameters discussed above are pre-
sented in Tables 9 and 10. Treatment aspects are dealt with
briefly, and a fuller account can be found in the report of the
Management and Therapy Subcommittee.
Overall Recommendations. The recommendations of the
Diagnostic Subcommittee are as follows and are summarized in
Table 11:
MGD is a common disorder that may be asymptomatic or give
rise to symptoms, either confined to the affected lids or arising
from MGD-related ocular surface disease, including evaporative
dry eye. It can also exacerbate aqueous-deficient dry eye.
The natural history of MGD is not precisely known; for
practical purposes it should be regarded as a progressive but
treatable disease in which therapy may prevent irreversible
changes. This approach is a safe one that can be modified as
further information becomes available.
Therapy is based on diagnosis and a decision to treat depends
on the severity of disease. While simple diagnosis is straightfor-
ward, quantification of the degree and severity of MGD, which is
the basis for treatment, is more complex.
A two-step approach to diagnosis is recommended in symp-
tomatic patients. The assessment of meibomian gland function is
based on lid morphology, gland dropout, meibum expressibility,
TFLL appearance, and tear evaporation. A diagnosis of dry eye is
established from measures of tear production and clearance,
tear osmolarity and tear film stability, and the presence of
ocular surface changes by tissue staining and perhaps fur-
ther characterized by the presence of inflammatory biomark-
ers. Patients with symptoms of ocular surface disease should
be assessed for ocular surface damage and for abnormalities
of tear dynamics characteristic of dry eye (Table 8).
Quantification of MGD is based on grading meibum quality
and expressibility. When the presence of MGD is more than
trivial and treatment is instituted, the score should be noted
and repeated periodically at follow-up. An aggregate score
derived from the expression of upper and lower, central, and
nasal lid zones should be considered as a method of monitoring
the response to treatment. Newer, quantitative methods of
expression may make grading more accurate in the future.
Although such grading approaches have been used to dif-
ferentiate mild from severe disease, their repeatability is un-
known, and therefore their value in demonstrating small
changes in disease severity is unknown. There is good evi-
dence that meibomian gland dropout is closely associated with
MGD severity. It is therefore recommended that, when possi-
ble, baseline measurements of gland dropout be made by using
meibography. Baseline measurements can be used for stratifi-
cation purposes in clinical trials, but when such trials are
extended, or in natural history studies or where meibomian
gland damage occurs as an adverse event, they may provide a
record of change over time.
IV. APPENDICES
Method of Working
Each reviewer used the following format when analyzing the
diagnostic tests:
1. Identify the test.
2. Provide rationale for use.
3. Describe each of the techniques used in full detail.
Wherever available, test values for normals, MGD and dry
eye were identified, together with the sensitivity and specific-
ity of the test and recommended or reported diagnostic cutoff
values. In those cases in which published papers included the
diagnostic effectiveness of the test, these values were included
in the reviewer’s report. Throughout the appendices, in the
tables the following abbreviations are used: N, normal subject
(i.e., no dry eye); DE, dry eye; EDE, evaporative dry eye; ADDE,
aqueous-deficient dry eye.
APPENDIX 1
Test Identification: Symptom Questionnaires
A wide range of questionnaires have been used to assess the
symptoms of ocular discomfort associated with dry eye condi-
tions.148–152 Extensive reviews of the utility of these question-
naires have been published elsewhere.153,154 Despite the nu-
merous questionnaires available, those most commonly used
show good agreement.155
Rationale
Questionnaires allow the assessment of a range of symptoms
associated with ocular discomfort. However, due to the
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commonality of symptoms across a range of disorders in-
cluding dry eye and MGD,156 these questionnaires are un-
likely to be able to differentiate between etiologically dis-
tinct disease entities. Despite this limitation, some studies
have looked at the role of questionnaires in assessing symp-
toms in MGD.
Method and Description
Studies have shown that MGD (diagnosed by gland orifice
plugging and lid margin telangiectasia) is present in 61.7% of
symptomatic patients.157 This was in close agreement with
other studies where 63.6%158 and 64.6%159 of symptomatic
TABLE 11. Assessment of Meibomian Gland Function
Based on Meibomian Gland Expression
Grades and comments
Methods: A plus Ba or Bb
A. Meibum quality: LL or UL, central 8 glands
0  clear fluid
1  cloudy fluid
2  cloudy particulate fluid
3  inspissated, like toothpaste.
Ba. Meibum expressibility: LL or UL, central 8 glands
0  all glands expressible
1  3–4 glands expressible
2  1–2 glands expressible
3  no glands expressible
Bb. Meibum expressibility: LL nasal or central eight glands
The MGYLS score is the number of Meibomian Glands of eight, Yielding Liquid Secretion.
Assessment by gland expression
20 years: A score of greater than 1 for quality or expressibility (A; B) is abnormal.
20 years: A score of 1 for either quality or expressibility is acceptable as normal; a score of 1 for both, or of 1 for either, is abnormal.
For research and some clinical trial purposes, the utility of this approach would be enhanced by generating a composite score derived from
the expression of the LL, UL nasal and central zones.
Based on Meibomian Gland Dropout
Meibography: The technique of meibography offers an excellent opportunity to refine the quantification of gland loss by digitizing the images.
It should be noted that estimates of ’gland loss’ are based on an assumption of the original size of ea ch gland. Therefore estimates of
residual gland area will be more accurate, although relevant to a particular individual. There is a need for detailed age/sex stratified
information about gland area.
A precise description of any technique proposed must be given. For example, if the term ’partial gland loss’ is used, this must be defined. An
estimate of loss is based on the presumed, intact length of each gland. Training would be enhanced by the use of videos showing
both the performance of the technique of method of scoring in use.
Either contact or noncontact meibography can be used.
Method C: LL 15 glands: A partial gland is one that is incomplete and present in clumps or clusters.
1  no partial glands (PGs)
2  25% PGs
3  25%–75% PGs
4  75% PGs
An aggregate score from the combined LL/UL would expand the scale
Method D: (nasal half, lower eyelid)*
0  no dropout
1  25%
2  50%
3  75%
4  100%
Based on Meibography
20 years. Method C. Normal is 0
20 years. Method C. 1  25% is acceptable as normal; 1 is abnormal
Diagnosis of MGD-related disease, including dry eye:
In the general clinic. See Table 8
In a specialized clinic. See Table 8
MGD Criteria for Specific Purposes
1. Clinical practice: See diagnostic criteria above
2. Recruitment for clinical trials
a. Therapy of ADDE. Accept a mild degree of MGD. Record the grade of MGD on the basis of gland expression and with or without baseline
dropout. Use data for stratification in data analysis.
b. Therapy for MGD. Recruit patients with moderate to marked MGD. Establish criteria for irreversible disease’ and ensure that the each
individual in the sample has sufficient reversible MGD to make treatment viable
3. MGD as a potential adverse event
In studies that aim to detect and monitor meibomian gland changes as an adverse event the population should be young adults (40 years)
to minimize baseline MGD scores and maximize detectability of change.
4. Natural History of MGD
Studies of the natural history of 1° and 2° MGD are required, in patients on or off treatment. There are no specific recruitment criteria.
* de Paiva et al.106 have also devised a composite score including lids signs and expressibility, with a scale range of 0–11.
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subjects were found to have signs of MGD. A higher proportion
of MGD sufferers were found (74.3%) among symptomatic
video display unit (VDU) users but this is likely to be due to the
population studied. Interestingly, in this VDU population MGD
sufferers did not exhibit more severe symptoms than subjects
with no evidence of MGD.160 Further evidence for the role of
MGD in producing symptoms comes from the observation that
a statistically significant negative correlation was observed be-
tween the number of meibomian glands capable of yielding
liquid secretion and symptom score.161
It is clear from these studies that MGD is present in excess
of 60% of patients with ocular discomfort. Current question-
naires have not been optimized or tested in their ability to
differentiate between MGD and other causes of ocular discom-
fort. Undoubtedly, further studies are needed, particularly to
assess the sensitivity and specificity of symptom questionnaires
in the diagnosis of robustly defined MGD patients. Because of
the commonality of symptoms with other disorders and the
lack of a pathognomonic symptom in MGD, it is likely that
questionnaires, although useful, will have to be used in con-
junction with other methods in the characterization and diag-
nosis of MGD.
Of interest, the Ocular Surface Disease Index (Allergan Inc.,
Irvine, CA) has been recently validated across ocular surface
disease severity,162 and while the symptoms may be different
in MGD, it can be hypothesized that the OSDI could be used to
document disease progression. The ocular surface disease rat-
ings are as follows across the scale of the questionnaire (0–
100): normal, 0–12; mild, 13–22; moderate, 23–32; and severe,
33–100, with a seven-unit change noted as clinically signifi-
cant.162
APPENDIX 2
Test Identification: Fluorescein/Noninvasive
Breakup Time
Breakup time is thought to be a surrogate measure of tear
stability.
Rationale
Tear breakup time (TBUT) is generally regarded as a test for
diagnosis of evaporative dry eye; however, as discuused herein,
TBUT testing is relevant in the diagnosis of MGD. Tear film
instability is one of the core mechanisms of dry eye and may be
the initiating event.163 It is dependent on many factors, includ-
ing an adequate tear film lipid layer,164–171 which in turn is
dependent on meibomian gland function.166,172,173 There is
strong evidence to suggest that both lipid quantity and quality
correlate with meibomian gland function and dry eye
states.165–169,172–178 Hence, low TBUTs imply a possibility of
lipid layer compromise and thus meibomian gland dysfunction,
whereas high TBUTs suggest a normal lipid layer and adequate
meibomian gland function.164,168,170,171 Thus, whenever TBUT
is low, meibomian gland function and expressibility should be
investigated for diagnosis and in considering treatment.
Description: Fluorescein Breakup Time
Tear film stability is measured by a test of fluorescein breakup
time (FBUT), defined as the time to initial breakup of the tear film
after a blink.179 It has been proposed that fluorescein breakup can
be caused by quenching of fluorescence related to the increase in
fluorescein concentration caused by evaporation.180 The classic
and usual method to determine breakup time utilizes fluorescein
to stain the tear film (FBUT).181–183 The fluorescein may be
applied by wetting a commercially available fluorescein-impreg-
nated strip with sterile saline and applying to the inferior fornix or
to the bulbar conjunctiva. After instillation, the patient is asked to
blink several times and to move the eyes, to mix the fluorescein
in the tears. Observation is with the slit lamp, a cobalt blue filter,
a beam width of approximately 4 mm, and full height, and the
beam is slowly moved from side to side to cover the entire
cornea.182,183 A yellow barrier filter enhances observation of the
fluorescent tear film.179,184 The patient is instructed to blink
naturally and then, once homogeneous tear film fluorescence is
confirmed, to keep the eyes open while looking straight ahead.
The time from upstroke of the last blink to the first tear film break
or dry spot formation is recorded as the FBUT measurement.
Either one or the average of three consecutive trials is the final
value.178,179,182,184,185 Optionally, a video camera may be used to
record TBUT with various methods used to automate timing and
permit masking of the measurement.179,184 An alternative to the
use of fluorescein-impregnated strips is the instillation of liquid
unpreserved fluorescein onto the bulbar or conjunctival conjunc-
tiva with a micropipette. Concentrations of 2% to 5% and volumes
of 1 to 5 L have been advocated179,186 (Welch D, et al. IOVS
2008;49:ARVO E-Abstract 2485). The observation procedure is
the same as for the fluorescein-impregnated strip.
In performing a series of clinical tests for dry eye, measure-
ment of the TFBUT is usually followed by measurement of
fluorescein staining. There is a distinct advantage in complet-
ing the series in the right eye, before instilling dye and per-
forming the series in the left eye, since this avoids dilution of
dye in the tear film and diffusion of dye taken up into the
ocular surface of the second eye (Appendix 4).
Variations in the Technique of Administering the
FBUT Test. Despite the acknowledgment of the value of quan-
tification of tear film stability, FBUT has been criticized as being
inaccurate and poorly reproducible186–190 (Welch D, et al.
IOVS 2008;49:ARVO E-Abstract 2485). The inherent nature of a
large fluorescein-impregnated strip and the lack of a standard-
ized procedure for moistening and applying the strip to the
tear film prevents control of the volume delivered to the tear
film and must result in variability. There is no agreement as to
whether the moistened strip should be shaken before instilla-
tion or whether the strip should be applied to the superior,
inferior, temporal, or inferior temporal bulbar conjunctiva or
to the tear meniscus.169,178,182,185–187
The greatest source of variability in FBUTs relates to the
volume of fluorescein delivered. FBUT measurement reliability
is increased when 2 L or less of a 5% fluorescein solution is
applied with a micropipette versus the conventional strip
method.179,186 Although micropipettes offer a precise method
of instillation of microliter quantities of fluorescein, the use of
unpreserved fluorescein solutions in the clinical setting re-
quires sterile procedures, and while these prodecures are ap-
plicable to research studies, they are not readily adaptable to
clinical practice. Further, FBUTs are altered by reflex tearing,
and the use of a pipette frequently causes apprehension in the
patient and reflex tearing. A novel approach to both reducing
the volume of fluorescein and eliminating sensation and reflex
tearing during FBUT measurements, the Dry Eye Test (DET;
Nomax, Inc., St. Louis, MO) was developed to deliver 1 L of
fluorescein solution to the tear film by application to the
superior temporal bulbar conjunctiva.184 The DET is applicable
in either research studies or clinical practice.179,184
Recommendations for Conduct of the FBUT Test. Ei-
ther the micropipette or the DET strip is applicable for research
studies. The micropipette method should be standardized for
volume and concentration of fluorescein. Recommendations for
volume have varied from 5 to 1 L and for concentration from 1%
to 5%.179,186 The DET strip provides a standardized method to
deliver 1 L of volume.185
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Estimated Values of FBUT in Normal, Dry, and MGD
Eyes. There are no reported estimated values for subjects with
only MGD specifically.
With traditional volumes of fluorescein, FBUTs in normal sub-
jects are 10 seconds versus 10 seconds in those with dry
eye.179,191 With micro volumes of fluorescein, FBUTs in normal
subjects are 5 seconds versus 5 seconds in dry eye.179,192
Sensitivity and Specificity. The sensitivity and specificity
of the FBUT test are reported to be 72% and 62%.169
Method and Description: Noninvasive Breakup
Time Measurement
Noninvasive breakup time (NIBUT) measurement utilizes a grid
or other pattern projected onto the precorneal tear film for the
observation of distortion and/or abnormalities in the image.189
The patient is instructed to blink normally while looking
straight ahead. The time interval in seconds from the upstroke
of a blink to the first change of the image after a blink is defined
as the NIBUT. The result of either one or the average of three
consecutive trials is the final value.178,179,182,184,185 Optionally,
a video camera may be used to record TBUT with various
methods to automate timing179 (Welch D, et al. IOVS 2008;49:
ARVO E-Abstract 2485).
The NIBUT test eliminates physical disturbance of the tear
film from the instillation of fluorescein, along with the possi-
bility of inducing tactile reflex tearing.169,179,188,189 NIBUT
would therefore appear to be an ideal theoretical method of
evaluating tear film stability, because it overcomes the objec-
tions to fluorescein invasive FBUT measurement and can pro-
vide more reliable and reproducible results. The TBUTs ob-
tained with the NIBUT test are significantly greater than those
values found with the FBUT,169,170,182,193–195 which has been
attributed to the destabilizing effect of the instilled fluorescein.
A study advocating the use of the NIBUT test for the diagnosis
of mucous layer deficiencies and for distinguishing between
aqueous tear deficiency and MGD nevertheless stated that the
NIBUT test did not replace the FBUT test as the test of choice
for the evaluation of tear film stability.169
Estimated Values of NIBUT in Normal, Dry, and MGD
Eyes. The normal range for NIBUT is typically 40 to 60 sec-
onds193 compared with normal ranges of 10 to 34
seconds181,194for the FBUT. For dry eye NIBUT 10 sec-
onds.190 Reported values of NIBUT vary significantly between
investigators and equipment used, with the values of NIBUT
remaining higher than those for FBUT.170,195 It has been sug-
gested that the two methods measure different phenomena.169
There are no specifically reported estimated values for subjects
with only MGD.
Sensitivity and Specificity. The sensitivity and specificity
of the NIBUT test are reported to be 82% and 86%.189
APPENDIX 3
Test Identification: Schirmer test (in the
Diagnosis of MGD)
The Schirmer test is traditionally a measure of tear production
when performed for the recommended 5 minutes, although
some research indicates that the test, when administered for
shorter durations, may be a measure of tear volume on the
ocular surface.
Rationale
The Schirmer test may not be a direct test of MGD; however,
it is useful in the differentiation of aqueous-deficient dry eye
and evaporative dry eye, both of which may occur concur-
rently with MGD. Although MGD may be a causative factor in
evaporative dry eye, aqueous-deficient dry eye can occur si-
multaneously.
Method and Description
The Schirmer test without anesthesia is a well-standardized test
performed with the patient’s eyes closed.196 There is wide
intrasubject, temporal, and visit-to-visit variation, but the vari-
ation and the absolute decrease in aqueous deficiency are
mostly due to the decreased reflex response with lacrimal
failure. When the cutoff value is set at5.5 mm/5 minutes, the
sensitivity and specificity of the testing are 85% and 83%,
respectively.197
The diagnostic cutoff used at present is 5.0 mm in 5
minutes, the reason for which is still unclear. Lowering the
cutoff decreases the detection rate (sensitivity), but increases
the specificity of the test.196 The repeatability of the Schirmer
1 test appears to be better with lower values (i.e., in more
severe aqueous deficiency).198 A significant correlation was
shown between Schirmer 1 test, tear stability and fluorescein
staining in a recent study by Nichols et al.199 Meibomian gland
disease greater than grade 1 (according to the method of Bron
et al.196) did not appear to correlate with the Schirmer 1 result,
tear meniscus height, phenol red test, and staining with vital
dye in that study. Nichols et al.200 reported a poor correlation
between Schirmer 1 test and dry eye symptoms. Many studies
showed that no significant differences existed in tear quantity
(Schirmer 1 test values) between patients with simple MGD
and healthy control subjects, suggesting the difficulty of differ-
entiating MGD patients from normal subjects based only on
tear quantity.201–204 Shimazaki et al.205 and Goto et al.206
found no differences in Schirmer 1 test scores between pa-
tients with Sjo¨gren’s syndrome and those with non-Sjo¨gren’s
syndrome dry eye. However, the presence of MGD in associa-
tion resulted in much more severe ocular surface disease char-
acterized by higher fluorescein and rose bengal vital staining
scores or tear evaporation. Den et al.207 found that changes in
the lid margin, including vascular engorgement, irregularity,
plugging of MG orifices, and replacement of the MCJ were
closely related to aging and that there was an age-related
decrease in tear quantity scores assessed with Schirmer 1 test.
Subjects with Schirmer test scores 5 mm had significantly
decreased meibomian gland expressibility grades. Arita et al.208
found an age-related decrease in Schirmer 1 test scores and
meibomian gland dropout grades in a recent study. Sterile
Schirmer test strips were used to collect meibomian oil in
healthy individuals (n  20), dry eye patients (aqueous-defi-
cient; n 32) and MGD patients (n 25) after gentle massage
of the lid margin in another study.209 Meibomian fatty acids
were directly transmethylated and analyzed by using gas chro-
matography (GC) and GC mass spectrometry. Meibomian fatty
acids were similar in healthy individuals and in dry eye patients
with aqueous deficiency, but were different in MGD patients,
who showed significantly higher levels of branched-chain fatty
acids (29.8% vs. 20.2%) and lower levels of saturated fatty acids
(9.3 vs. 24.6%)–-in particular, lower levels of palmitic (C16)
and stearic (C18) acids. The increase in branched-chain fatty
acids may reflect greater quantities of wax and cholesterol
esters and triglycerides in meibomian gland excreta. It was
concluded that meibomian fatty acid composition and partic-
ularly the increase in branched chains evaluated with Schirmer
strips could be a marker for meibomian gland dysfunction. The
methodology also proved to reflect treatment effects by oral
minocycline treatment suggesting iso-C20 (extracted from
Schirmer strips) to be a useful biomarker for the diagnosis of
MGD.210
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Test Identification: Phenol Red
(Cotton Thread) Test
The phenol red test (PRT) test has been developed as an
alternative to the Schirmer test and is another method of
analyzing a patient’s lacrimal system.
Rationale
The PRT tear test represents another approach to the analysis
of a patient’s lacrimal system. It was developed to overcome
the disadvantages of the Schirmer tear test, including variable
results, poor repeatability, and failure to measure basal secre-
tion, even when used with anesthesia.
Method and Description
Although the PRT method is quite similar to Schirmer, there
are distinct differences. There is little or no sensation of the
thread, making anesthesia unnecessary. A test time of only
15 seconds is required in comparison to the 5 minutes per
eye needed for the Schirmer test. This test is performed with
the patient’s eyes open while blinking naturally. The length
(in millimeters) of the wet portion of the thread is recorded
as the result. Because of the short test time and minimal
sensation of the thread, it is theorized that this test gives an
indication of amount of residual tears located primarily in
the inferior conjunctival sac of the eye.211 Using a cutoff
value of 12 mm, the sensitivity and specificity of the PRT are
56% and 69%, respectively. Even if the agreement with the
Schirmer 1 test is highly significant, 32% of patients have
discordant results. These two methods of functional assess-
ment of tear secretion seem to be complementary, and further
studies remain necessary to better understand the correlation of
both tests in clinical practice.212 A recent study found a weak
agreement between Schirmer test and phenol red thread tests and
between each test and symptoms of dry eyes.213 To determine
the clinical viability of a phenol red–impregnated cotton thread in
differentiating between normal, aqueous deficient, and non–aque-
ous-deficient dry eyes, Patel et al.214 recruited subjects on the
basis of subjective symptoms, tear stability, rose bengal staining,
Schirmer test, conjunctival hyperemia, patency and number of
meibomian glands, presence of mucin strands, and appearance of
lower tear meniscus. Based on the outcome of the tests, the
subjects were categorized as having aqueous-deficient dry eye,
non–aqueous-deficient dry eye, or normal eyes. Subjects were
randomized, and a thread was applied by inserting it into the
lower fornix of the right eye and leaving the thread in place for
120 seconds. The mean thread-wetting values were 15.5  4.7
mm in aqueous-deficient dry eyes (n  35), 22.7  5 mm in
non–aqueous-deficient eyes, and 19.4 5 mm in the normal eyes
(n  38). For the aqueous-deficient and non–aqueous-deficient
dry eyes only, when a cutoff value of 20 mm was used, the
calculated sensitivity and specificity were 86% and 83%, respec-
tively.196,214 PRT was found not to have any correlation with
MGD (in patients with more than grade 1 MGD as classified by
Bron’s grading scheme) by Nichols et al.199 The test was also
found to have poorer repeatability than the Schirmer test.198 The
test was removed from Japanese dry eye diagnostic criteria on the
founder’s request due to low repeatability and wide variation in
scores.214
APPENDIX 4
Test Identification: Ocular Surface Staining
Rationale. Ocular surface damage is encountered in asso-
ciation with MGD and is found in its most advanced form in
MKC. Various etiologies have been proposed for such damage,
including the release of inflammatory mediators into the tear
film215,216 and the mechanism of evaporative dry eye.217 One
source of such mediators includes the breakdown products of
meibomian lipids altered by the lipases of microbial commen-
sals.218–221
Ocular surface damage may be quantified by grading stain-
ing of the cornea and conjunctiva by using selected dyes, by
immunohistochemistry, or by flow cytometry on impression
cytology specimens and the direct measurement of inflamma-
tory mediators in the tears biochemically or with multiplex
beads, matrix assisted-laser desorption ionization (MALDI)-TOF
(time of flight), and proteomic techniques222–224 (Reinoso R, et
al. IOVS 2009;50:ARVO E-Abstract 517; Topcu Yilmaz P, et al.
IOVS 2009;50:ARVO E-Abstract 3592; Calonge M, et al. IOVS
2009;50:ARVO E-Abstract 2548); Nichols KK, et al. IOVS 2009;
50:ARVO E-Abstract 541).
Additional approaches include confocal microscopy (Ap-
pendix 8). These techniques have helped to describe the ocu-
lar surface phenotype in MGD and other ocular surface dis-
eases and to monitor the severity of disease and response to
treatment, but the events that they record are not specific to
MGD, and therefore they have no unique role in diagnosis. The
precision of such tests was addressed in the 2007 DEWS re-
port,196 where details of their sensitivity and specificity in the
diagnosis of dry eye is summarized and incorporated, both in
the published templates and in additional materials available on
the TFOS web site. In addition to the DEWS Management and
Therapy report,225 ocular surface staining was cited as an
important diagnostic criterion by Behrens et al.226 in the clin-
ical diagnosis of ocular surface disease.
Method and Description
Grading Ocular Surface Staining. Several grading
schemes have been reported and are discussed below.
1. van Bijsterveld227
2. NEI/Industry Schema228
3. Oxford Grading System.229,230
van Bijsterveld. One drop of rose bengal 1% is instilled.
Staining is graded 0 to 3 on the cornea and for two exposed
conjunctival segments (range: 0–9).
In the European/American criteria for the diagnosis of
Sjo¨gren Syndrome231 a 2.5 L solution of rose bengal is in-
stilled in the lower fornix. Grading is according to van Bi-
jsterveld 1969.227 The sensitivity/specificity of rose Bengal
staining is as follows:
NEI/Industry Schema. Nichols et al.232 used a modified
version in dry eye diagnosis. The grading proforma presents
five corneal and 2 3 conjunctival zones. Grades are 0 to 3 per
zone, including 0.5 steps. Fluorescein or rose bengal is instilled
from impregnated strips in control and dry eye subjects. There
is strong agreement between corneal and conjunctival staining.
A revised version of this test, incorporating features of the
NEI/Workshop grading system and the Oxford system (dubbed
Cut-off: <3.5 N vs. DE N vs. EDE ADDE vs. EDE
Sensitivity/specificity 95% vs. 96% NA NA
Cut-off: <4 N vs. DE N vs. EDE ADDE vs. EDE
Sensitivity/specificity
in diagnosis of SS 63% vs. 84% NA NA
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the Oxford version 2),230 was presented as a poster at a Tear
Film and Ocular Surface meeting (Taormina, Italy 2006).The
purpose was to provide a finer scale and to standardize the
conduct of the test. The NEI/Industry system has been modi-
fied to (1) standardize the size and location of recording zones
and (2) to create panels of random dots whose increasing
density in numbers from panel to panel is mathematically
defined. To do this (1) a series of 10 panels is generated, with
the probability P that a pixel would be black given by P 
exp(0.9  a)/exp(0.9  b)  k, where a is the number of the
current panel, b is the number of the last panel  1, and k 
0.00042. So that the dot size on the printed panels approxi-
mates that of a staining point on the ocular surface, the panels
are scaled in a word processing program (MSWord; Microsoft,
Redmond, WA), so that the dot size reflects the apparent size
of an epithelial cell at the magnification used at the slit lamp.
The grading range for each zone is from 1 to 10. Therefore,
since the number of zones scored is 2 3 conjunctival and five
corneal, the grade range is from 0 to 110. The system has not
yet been validated.
Oxford Grading System. In this system the cornea and
two conjunctival zones are graded, with a grade score 0 to 5
per zone (total range, 0–15). In an intra-observer study, two
trained ophthalmologists graded a series of standard slides,
showing corneal and conjunctival fluorescein staining, on two
separate occasions. In an inter-observer study the same two
observers graded fluorescein (blue exciter; yellow filter) and
rose bengal in 13 dry eye patients at an interval between 2 and
3 weeks. The  values were in the good to excellent range in
the assessment of the standard slides. In dry eye patients, the 
values were in the excellent category for for cornea, but in the
fair category for conjunctiva.233
Additional studies have been undertaken to explore the utlility
of batteries of tests, including symptom questionnaires, ocular
surface staining, Schirmer test, fluorescein clearance test (FCT),
and corneal sensitivity, in the diagnosis of dry eye. These are
summarized under the heading of mixed tests in the dry eye
templates published in the DEWS (2007) report. In a study by
Afonso et al.234 in patients with irritative ocular surface symp-
toms, meibomian gland dropout or orifice metaplasia correlated
significantly with reduced fluorescein clearance and inversely
with the Schirmer result.
APPENDIX 5
Test Identification: Signs of MGD in
Lid Morphology
Rationale. The classification of MGD is based on clinical
findings. Some recent classifications have used a terminology
based on functional andmicrobiologic associations.235–239 McCul-
ley et al.240 have suggested that the clinical spectrum of chronic
blepharitis has changed and that the relative prevalence of Staph-
ylococcus aureus, alone or in combinationwith seborrheic bleph-
aritis, has decreased. In the literature and clinically, it has been
hypothesized that the relative prevalence of seborrheic blephari-
tis has increased, with or without associated excess meibomian
secretions (meibomian seborrhea) or inflammation (meibomitis).
The terminology used clinically has been inconsistent, and the
The Report on Definition and Classification has the specific pur-
pose of unifying terminology. Nonetheless, clinically, primary
meibomitis appears not to be a primarily infectious entity but to
represent a facet of generalized sebaceous gland dysfunction
found in association with seborrheic dermatitis or acne rosacea.
These entities are recognized as chronic diseases requiring con-
trol for which there is no cure.
Additional attempts have been made to incorporate morpho-
logic features of meibomian abnormality occurring in the gland
acinus, duct, or orifice.241 Before meaningful classification of
MGD morphology can be performed, it is important to define the
normal anatomy of the lid and meibomian gland apparatus and its
associated age-related changes.242 The appearance of the normal
lid then can be used to provide a basis for a morphologic classi-
fication of posterior blepharitis, enabling better correlation with
MGD and the earlier recognition of the diseased lid. Clinical
descriptions of lid margin changes across age (children to elderly)
are summarized below.235–246
Lid Margin. The lid margin thickness has a normal range for
adults and children. The lid margin in adults is 2 mm thick at its
free edge and has lashes on its anterior aspect. Lid margin thick-
ness in children ranges between 1.43 and 1.63 mm in the upper
lid and 1.41 and 1.61 mm in the lower one. From adolescence
onward, lid thickness increases to between 1.88 and 2.02 mm in
the upper lid and 1.81 and 1.93 mm in the lower lid.242 The lid
thickening that apparently occurs after childhood may be related
to enlargement of the orbicularis muscle. Hormone-induced en-
largement of sebaceous glands at puberty and could affect the
meibomian glands.
Lid Vascularity. The lids of children are typically less vascu-
lar, with no telangiectasia, cutaneous hyperkeratinization, or squa-
mous blepharitis. The absence of lid margin vascularity in chil-
dren is striking, and the increase from adolescence may be
secondary to increased MGD. In the elderly, telangiectasia, and
cutaneous hyperkeratinization are significantly more common in
the lower lid. This perhaps reflects increased exposure of the
lower lid to various insults, including ultraviolet radiation. The
increased prevalence of upper lid margin rounding in the elderly
has not been thought of as a physiological finding and is generally
considered to be more common in the lower lid, in association
with posterior blepharitis and subconjunctival fibrosis. Other fac-
tors, such as exposure at work to dust particles, urbanization, and
cosmetics may be important.
Cilia. The cilia count in the sagittal plane does not change
significantly with age; however, it is a clinical impression that loss
of cilia occurs in elderly patients, as does hair loss elsewhere in
the body.
Mucocutaneous Junction. The MCJ is constant in position
immediately posterior to the meibomian gland orifices. The
MCJ lies at the junction of the anterior two thirds and posterior
one third of the lid, but may run an irregular course in normal
elderly persons. No significant age-related changes in the po-
sition or form of the MCJ have been noted. Changes are
typically seen in disease states, particularly MGD, acne rosacea,
and severe atopic eye disease.
Orifices. The meibomian gland orifices are situated just an-
terior to the MCJ. The orifices are round, are rarely narrowed or
pouted, and no orifice obliteration or retroplacement occurs.
They may be congenitally absent, in association with the under-
lying gland and have been described as plugged by keratin and
desquamated epithelial cells, damaged, or patent in a nonsecre-
tory, resting phase. Plugging may eventually lead to obliteration of
orifices with atrophy of gland and duct. Meibomian gland orifice
narrowing and pouting showed an age-related increase in fre-
quency. Pouting is a feature previously reported in chronic bleph-
aritis. Orifice narrowing and pouting probably represent hyper-
trophy and keratinization of duct epithelium. Pouting of orifices
in asymptomatic individuals may be a feature of the aging lid as
well as an early sign of MGD. Narrowing of the orifices increases
with age, and the associated change in the shape of the surround-
ing epithelial cuff suggests that there is uneven distribution of
tissue stress in the coronal and sagittal planes of the lid margin.
Orifice obliteration is significantly increased with age in the upper
lid. It has been reported in MGD, acne rosacea, and severe mu-
cous membrane disease, such as trachoma and cicatricial pemphi-
goid, in which secondary MGD occurs, but not in normal sub-
jects.
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Main Duct. The glands themselves can be seen as yellow
streaks through the tarsal plate in young people. They have amain
duct opening on the lid margin at a meibomian gland orifice and
50 to 60 lateral ductules leading to a single or composite acinus.
They are modified sebaceous glands; the upper lid contains ap-
proximately 30 and the lower 20. The upper lid glands are longer
(10 mm) than the lower (5 mm).
Acini. These will be described in the section on meibogra-
phy.
Tarsal Plate. Lower lid conjunctival hyperemia occurs with
increasing frequency in elderly patients.
Secretions. A significant decrease in the quantity of secre-
tion occurs with age, with fewer orifices freely expressing
meibomian secretions. However, the decrease is usually not
accompanied by an increased opacity or viscosity of the secre-
tions, suggesting that these may represent markers of disease
and result in the typical plugging of meibomian gland orifices
in MGD.
Clinical Anatomy in MGD
Lid Margin. Thickening of the lid is a common feature of
meibomian gland disease, but is difficult to measure because of
the rounded contour of the anterior margin. It is best measured
from the posterior margin to the posterior lash line, which are
relatively constant features of the lid. Rounding of the posterior
lid margin is often associated with thickening and interferes with
the normal apposition of lid to globe. Vascularization increases
with age. In MGD, there is an exaggeration with invasion of the
outer and then inner cuffs of the orifice. Hyperkeratinization is
an eczematous appearance of the cutaneous margin, frequently
encountered in atopes with facial eczema, but also in nonatopic
subjects. Irregularity of the lid margin arises from absorption of
tissue, often in the region of obliterated meibomian orifices, but
will occur with more gross distortions of lid architecture in cica-
tricial and ulcerative lid disease.
Mucocutaneous Junction. The MCJ location and mor-
phology may be altered in MGD. The MCJ is best identified by
its specular reflection. Although the position of the anterior
edge of the tear meniscus may correspond with it in health, in
disease it may not be an accurate guide.
1. Anteroplacement. The junction becomes irregular in
MGD. The mucosa may spread forward, so that the
orifices appear to lie in mucosal tissue.
2. Retroplacement. There is a posterior movement of the
MCJ, with a spreading, keratinizing, squamous metapla-
sia of the posterior lid margin that extends onto the
tarsal plate. The meibomian orifices may or may not
move with the MCJ, which will determine whether the
tear oil is delivered onto the surface of the tear film.
Retroplaccment is more common than anteroplacement.
3. Mucosal absorption. This may occur without retroplace-
ment of the MCJ so that the MCJ and orifices are still at
the same distance from the lash line, but come to lie
closer to a new posterior lid margin.
4. Ridging. There is a ridgelike elevation of the MCJ or of
tissue between the orifices. It may also be a secondary
effect of mucosal absorption.
Orifices. Orifices demonstrate several presentations in
MGD.
1. Number. The orifices may be reduplicated, or reduced
in number, congenitally, sometimes as part of a syn-
drome, or as an acquired feature of MGD.
2. Capping. Scattered orifices may be capped by a dome of
oil with a tough surface, but may be pierced by a needle
tip to release the oil. The underlying orifice may be
ulcerated and the cap epithelialized. Capping usually
affects only occasional orifices and may be found in
otherwise normal lids.
3. Pouting. An early sign of MGD is the elevation or pout-
ing of the orifice, which is no longer flush with the
surface. The term is probably equivalent to plugging.
The meibomian orifice may be dilated, and expression
may demonstrate the terminal ductule plugged with in-
spissated secretion or other material.
4. Retroplacement. This term is used to describe the result
of a cicatricial process involving the posterior lid margin
and may be associated with more extensive cicatricial
changes within the tarsal mucous membrane near the
marginal mucosa. The orifices may become ovally elon-
gated at right angles to the plane of the lid margin, and
posterior movement may be accompanied by duct ex-
posure.
5. Obliteration narrowing. The punctum of the orifice
may not be visible. The appearance of narrowing is
accompanied by absent expressibility of lipid. Loss of
definition of the cuffs of the orifices is a feature that is
seen with age and in early MGD. Vascular invasion may
accompany the process of loss of definition.
6. Opaque orifices. The degree of opacity of the inner cuff
becomes accentuated. Opaque orifices are far more vis-
ible at the lid margin than normal. Scarring of the region
of the orifices may occur, with tissue loss and depression
of the surface. It is often accompanied by a range of
degenerative changes at the lid margin.
7. Duct exposure. Exposure of the terminal duct of the
gland in varying degrees is a common feature of MGD,
suggesting the presence of an irreversible cicatricial pro-
cess in the adjacent submucosa. The duct, as it forms the
orifice at the lid margin, is seen to turn on its side
anteroposteriorly, so that it becomes visible at the sur-
face of the lid margin. The outer cuff becomes lost from
view, whereas the inner cuff (the epithelial lining) and
the translucent zone (the presumed dermal layer) are
seen in profile. In the early stages, the duct may be
patent and functional; later it is not. The changes may
extend over the lid margin for several millimeters, which
raises the question of whether it is associated with duct
elongation or absorption of the distal part of the tarsal
plate.
8. Cystoid dilatation of duct. Cystoid expansion may be
seen anywhere along the course of the duct as a dark
round or ovoid region along the course of a meibomian
gland. Sometimes there are extended, cigar-shaped struc-
tures that seem to occupy the position of one or more
meibomian glands, but it is not easy to distinguish dila-
tation of the duct from that of the gland acini by routine
methods. Enlarged, distorted and also shortened glands
may be distinguished by meibography and confocal mi-
croscopy.
Acini. The acini are susceptible to age-related and disease-
associated alterations.
1. Visibility. As mentioned earlier, congenitally absent or
deficient glands are represented by deficient orifices.
Although the presence of ascini may readily be judged in
young, uninflamed lids, the visibility of the acini, when
viewed by diffuse illumination of the tarsal plate, de-
creases with age as well as in the presence of chronic
conjunctival inflammation. Observation can be im-
proved by meibography. Enlargement or reduction in
size of the glands may be recorded and concretions and
chalazia may be present.
2. Concretions may follow the line of the meibomian
glands and are believed to be deposits of lime salts
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within acini. The clinical features of chalazia are well
known and start as a firm, circumscribed, painless ele-
vation on the tarsal plate, visible and palpable through
the skin, which evolves slowly with time. The lesion is in
line with the tarsal gland that it replaces, and the corre-
sponding ductile orifice is occluded, with no oil being
expressible.
3. Chalazia occur more frequently under the upper than
the lower lid and more commonly in adults than in the
young. They may he single or multiple, and they may be
confluent. The lid may be sufficiently thickened to pre-
vent eversion. More than one lid may be affected. Mul-
tiple chalazia are said to be more frequent in young
people, especially seborrheic subjects with a history of
chronic blepharoconjunctivitis, but also occur in elderly
people or those with rosacea.
Secretions Expressed. The secretory functions of the mei-
bomian glands are assessed indirectly by compressing the tarsal
plate locally in relation to individual groups of orifices. This
prodecure may be performed with finger pressure, a cotton
tip, or a glass rod or with the Korb expression device, to
produce, in normal lids, a dome of clear oil over the orifices.
The quality of the expressed secretion that can be elicited in
this way in MGD is as follows:
1. Clear (i.e., normal).
2. Cloudy: diffusely turbid fluid secretions.
3. Granular: usually turbid fluid secretions, but contains
particulate matter. The color of these secretions varies
from whitish-gray to yellow.
4. Inspissated: a semisolid plug or a substance of toothpaste-
like consistency; may be extruded as a plug or curled
thread. Expression is usually delayed or requires extra pres-
sure. The material contains keratinized epithelial cells.
The classification scheme, while not complete, is compre-
hensive enough to permit a detailed assessment of meibomian
and lid morphology for the purposes of natural history and
therapeutic studies. The purpose of classifying the features of
MGD is the opportunity it provides to quantify them.
APPENDIX 6
Test Identification: Meibomian
Gland Expressibility
Rationale. Meibomian gland expression can be performed as
an indicator of meibomian gland function. In the normal patient,
a clear to light yellow oil (meibum) is excreted from the glands
when digital pressure is placed on the glands. Changes in meibo-
mian gland expressibility may be a valuable indicator of disease.
Method and Description
The only method to determine whether a specific meibomian
gland is functional and capable of providing secretion is to ob-
serve the secretion expressed from that gland. Since it is not
possible to observe the flow of secretion from an individual gland
during blinking or forced blinking, assessment requires express-
ing the meibomian gland with a physical force applied to the
outer surface of the eyelid, while simultaneously observing the
orifice of the gland with adequate magnification and conditions to
detect the outflow of meibomian gland secretion.247–263 There
are four types of expression:
1. Traditional diagnostic expression to determine habitual
meibomian gland functionality, usually described with-
out specifying the quantification of the physical force or
time of expression. The description of the force applied
has been limited to gentle or forceful.256,261,263 The usual
procedure is to digitally express the central glands with a
force that does not require a rigid surface on the inside
surface of the lid. The finger is usually used for the expres-
sion, although a spatula, glass rod, or paddle may also be
used.254,256,259,264 It is suggested that the expression
should be maintained for 10 to 15 seconds.264
2. Standardized force diagnostic expression to determine
meibomian gland functionality, using a newly developed
handheld instrument to provide a force of approximately
1.25 g/mm2 (0.3 PSI) to simulate the forces of the eyelids
on the meibomian gland(s) during deliberate or forced
blinking, thus determining the functionality of individual
meibomian glands.264 The instrument is designed to ex-
press one third of the lower lid margin, or approximately
eight glands simultaneously. The time for application of
this force is standardized at 10 to 15 seconds. It is informa-
tive to evaluate all three sections of the lower lid in that
manner. Standardized force diagnostic expression allows
us to determine “the minimum number of glands required
to provide an adequate lipid layer for tear film function.”265
3. Diagnostic expression to determine the likelihood of suc-
cessful treatment and gland rehabilitation. The forces
required for this diagnosis are of a magnitude which re-
quires the use of a rigid surface on the inner lid surface to
prevent the transmission of force to the globe, allowing the
potential expression of presecretory excreta (inspissated).
This process is diagnostic since it is assumed that if pres-
ecretory excreta can be expressed, the gland has the po-
tential to be treated. Q-tips, spatulas, and glass rods have
been used for application to the inner lid surface, while the
finger is usually used for the outer lid surface. The amount
of force has only recently been defined; frequently the
amount of force approaches the maximum that can be
tolerated by the patient, usually in the range of 15 to 20
PSI.266
4. Therapeutic expression for treating obstruction and/or
expressing undesirable secretion/excreta, such as hyper-
secretion or purulence. Therapeutic expression requires
forces of a magnitude that require the use of a rigid surface
on the inner lid surface to evaluate whether force can
express the obstructive keratinized epithelial material and
other excreta. Q-tips, spatula, and glass rods have been
reported for the application to the inner lid surface, while
the finger is usually used for the outer lid surface. The
amount of force has not been defined; however, the
amount of force is usually the maximum force that can be
tolerated by the patient, usually in the range of 15 to 20 PSI,
but if tolerated may be significantly greater.259,266,267
Obstructive MGD is now recognized to be the most common
cause of evaporative dry eye.256,268–272 It is imperative to note
that obstructive MGD may not be accompanied by obvious lid
inflammation and other signs of lid pathology, and thus masquer-
ade as nonobvious to the usual slit lamp examination. Thus,
despite a wide prevalence in the general population, nonobvious
obstructive MGD is usually overlooked due to minimally observ-
able clinical signs associated with this type of MGD.56,249,272 It is
therefore recommended that diagnostic expression be performed
when dry eye symptoms are present, even when there is no
obvious blepharitis, since the most prevalent form of MGD occurs
in the absence of obvious blepharitis, and can only be detected by
physical expression. After diagnostic expression, expression to
determine the likelihood of successful meibomian gland treat-
ment should follow. Therapeutic expression may be instituted as
indicated.249,254,268–272
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Estimated Values in Normal, Dry Eye, and
MGD Eyes
There are only three studies in which the the number of meibo-
mian glands yielding secretion was correlated to symptoms, and
no studies correlating to other ocular surface findings.250,264,273
These three studies examined lower lids only. With digital expres-
sion, if four or more of the central six to eight glands are open,
there is a low likelihood of dry eye symptoms. Using the instru-
ment for standardized force expression, if three or more of the
central six to eight glands are open, there is a low likelihood of dry
eye symptoms. For the entire lid, with digital expression, if 10 or
more of the approximate 24 glands yield secretion, there is a low
likelihood of dry eye symptoms. Using the instrument for stan-
dardized force expression, for the entire lower lid, if 6 or more of
the24 glands yield secretion, there is a low likelihood of dry eye
symptoms. Conversely if 4 or fewer of the 24 glands yield
secretion, there is a high likelihood of dry eye symptoms.
Sensitivity and Specificity
There are no sensitivity or specificity data for nonobvious
obstructive MGD. There is one study in which sensitivity and
specificity were determined for meibomian gland function in
blepharitis. The study reported the sensitivity/specificity data
as follows: meibomian gland expression of the upper lid, 86%/
73%, and for the lower lid, 53%/66% (McCann LC, et al. IOVS
2008;49:ARVO E-Abstract 1532).
Volume and Quality
Lipid Volume. Lipid volume has been assessed semiquan-
titatively by measuring the average diameter of the dome of
expressed lipid in millimeters, using the slit lamp after 5 sec-
onds of digital pressure on the lower lid.263,270,274 However;
this evaluation can only measure lipid secretion, which is of a
viscosity permitting the formation of a dome. The desired lipid
secretion is a clear fluid oil249,253,254 and cannot form a dome,
limiting the use of this technique to abnormal or presecretory
excreta. There are several references that provide information
for the total volume of meibomian glands; however, the data
do not provide clinically relevant information regarding mei-
bomian gland expressibility and function.275–277 Further, indi-
rect estimates of oil volume may be obtained by meibom-
etry.287,279 Presently, virtually all the aspects of the volume of
meibomian gland secretion require the development of metrics
and methods for their determination.
Lipid Quality. There are numerous studies analyzing the
various components of meibomian oil,280–284 but this is a
developing concept, since a defining study for determining
precise characterization of an optimal lipid layer has not been
published. Similarly, lipid viscosity has not been standardized,
although viscosity qualifiers such as thick, toothpaste-like, or
globular versus fluid can be useful clinically.249,253,254
APPENDIX 7
Test Identification: Meibography
Rationale. Meibomian gland tissue can be visualized by
using meibography. As such, gland atrophy can be assessed.
Method and Description
Meibography is a technique for observing and documenting
the morphology of meibomian glands in vivo. In the first
published report of meibography, white light from an illumi-
nator was applied to the conjunctival side of the everted eyelid,
and the images were documented on black-and-white film.285
In the most basic version, white light from a transilluminator is
applied to the cutaneous side of the everted eyelid, which
allows observation and documentation of morphologic
changes in meibomian glands from the conjunctival side once
the lid is everted. The images are documented on black-and-
white film,285,286 infrared film,287–289 a near-infrared CCD
video camera,290 or infrared CCD videocameras.291,292 In a
recent variation of the technique a near infrared290 or infrared
light source is used.291,292 In a recent study292 involving an
infrared filter and an infrared CCD videocamera, meibomian
glands were observed without a light source applied onto the
cutaneous side of the everted eyelid, which made the meibog-
raphy a patient-friendly examination.
The observable morphologic changes include gland loss
and gland shortening, which is quantified using scoring sys-
tems. Different authors used different scoring scales as follows.
Mathers and Billborough293 scored gland dropout by the num-
ber of whole or partial glands missing from the central two
thirds of the lower lid. Shimazaki et al.294 scored loss of the
meibomian glands in the lower eyelid according to the follow-
ing scale: grade 0 (no loss of meibomian glands), grade 1 (lost
area 50% or less than the observed area), and grade 2 (lost area
more than 50% of the observed area). Pflugfelder et al.246
scored partial or complete loss of the meibomian glands in the
lower eyelid by using the following scale: grade 0 (no loss of
meibomian glands), grade 1 (lost area less than one third of the
observed area), grade 2 (lost area between one third and two
thirds of the observed area), and grade 3 (lost area more than
two thirds of the observed area). Nichols et al.290 scored the
gland dropout using the following scale: grade 1 (no partial
glands), grade 2 (less than 25% of the image contains partial
meibomian glands), grade 3 (between 25% and 75% of the
image contains partial meibomian glands), and grade 4 (more
than 75% of the image contains partial meibomian glands).
Arita et al.246 scored partial or complete loss of the meibomian
glands using the following grades for each eyelid (meiboscore):
grade 0 (no loss of meibomian glands), grade 1 (lost area less
than one third of the total area of meibomian glands), grade 2
(lost area between one third and two thirds of total area), grade
3 (lost area more than two thirds of the total area). Mei-
boscores for the upper and lower eyelids were summed to
obtain a score from 0 through 6 for each eye.
As shown below, diagnostic cutoff values for the mei-
boscore offer promising sensitivity and specificity when nor-
mal eyes were compared with eyes with obstructive MGD in a
recent study.292
APPENDIX 8
Test Identification: In Vivo Laser Scanning
Confocal Microscopy
Rationale. Scanning confocal microscopy allows for in vivo
microscopy of ocular surface morphology in health and dis-
ease.
Method and Description
Confocal microscopy is a novel emerging noninvasive technol-
ogy that is useful as a supplementary diagnostic tool for the in
vivo assessment of the histopathology of many ocular surface
diseases and anterior segment disorders associated with dry
eye disease, including the in vivo examination of the bulbar
and palpebral conjunctiva and the meibomian glands.296–305 In
Normal vs. Obstructive MGD
Cut-off Aqueous-deficient dry eye 3
(Sensitivity/specificity) (83.0/90.0)
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studies related to MGD, in vivo laser confocal microscopy was
performed with a new-generation confocal microscope, the
Rostock Corneal Software Version 1.2 of the HRTII-RCM
(Heidelberg Retina Tomograph II-Rostock Cornea Module;
Heidelberg Engineering GmbH, Dossenheim, Germany).
Briefly, after the upper or the lower eyelid is everted, the
center of the Tomo-Cap containing 2 mg carbomer gel pre-
served with cetrimide (Comfort Gel; Bausch & Lomb, Berlin,
Germany) is applanated onto the palpebral conjunctiva, and
the meibomian glands are scanned while moving the applanat-
ing lens from the lids margins toward the fornix with minute
vertical movements. The meibomian glands are also scanned
while the applanating lens is moved along the entire lid length
with minute horizontal movements. It is recommendable to
scan the temporal, central, and horizontal lid with the side
camera attachment and to make notes of which sequences
belong to which anatomic location in the lid margin, for ease
in the later analysis. The examination time for each eyelid takes
approximately 5 minutes. To reduce patient discomfort from
touch, a drop of topical anesthetic is applied. No patient
discomfort or any adverse effect related to this examination has
been observed or reported.
In the examination of the MGD, the longest and shortest
acinar unit diameter, periglandular inflammatory cell density,
and acinar unit density have been recommended and found to
be efficient parameters to evaluate the morphologic changes in
the meibomian glands.304,305 The density of glandular acinar
units and inflammatory cell density can be measured with an
internal software. Clearly visible acinar units are all counted in
a 400  400-m frame, and the acinar density is described as
the number of units per square millimeter. The longest and
shortest diameters in micrometers can be calculated by using
Image J software (developed by Wayne Rasband, National In-
stitutes of Health, Bethesda, MD; http://rsb.info.nih.gov/ij/in-
dex.html). Three randomized, nonoverlapping, high-quality
digital images of the nasal, middle, and temporal lower eyelid
(total of nine images per eyelid or more) can be used for
calculation of the confocal microscopy parameters. A recent
report concluded that acinar unit density and diameter seem to
be two promising new confocal microscopy parameters,
which are believed to aid in the diagnosis and evaluation of
simple MGD.304
In vivo confocal microscopy has been reported to be useful
in describing the phenotypic alterations in MGD, such as sub-
epithelial fibrosis, obstruction of meibomian gland orifices,
cystic dilatation of the ducts, and lipid/glandular secretory
accumulations in the acinar units and the ducts.305,306 Inflam-
matory cell density also seems to serve as a new and promising
diagnostic parameter of in vivo confocal microscopy for eval-
uation of treatment responses in advanced obstructive MGD as
well. In another recent study, a few periglandular inflammatory
cells were noted in the eyelids of healthy control subjects (20
eyes of 10 subjects; mean age, 66.4  8.9 years; mean inflam-
matory cell density in in vivo confocal microscopy, 50  30
cells/mm2). The number of inflammatory cells in the eyelids of
patients with obstructive MGD before treatment was observed
to be approximately 10 to 30 times higher than in those of
healthy control subjects. These observations suggest the po-
tential of this novel technology in differentiating inflammatory
obstructive MGD from noninflammatory subtypes and the po-
tential for evaluating the outcome of different treatment pro-
tocols.305 The caveat for this parameter is that the current
resolution of in vivo confocal microscopy cannot differentiate
between inflammatory cell subtypes, except for dendritic cells
and polymorphs. In vivo and ex vivo observations made with
this new technology have the potential to overcome this dis-
advantage. In testing the applicability of the aforementioned
confocal microscopy–based parameters in the diagnosis of
MGD with an expressibility grade 2 (Shimazaki grading) and
a meibomian gland dropout grade of 2 (Shimazaki: loss of
50% of glands along the entire eyelid), the receiver operating
characteristic curve technique has recently been used to de-
lineate the sensitivity, specificity, and cutoff value for each
parameter. In this study,307 20 right eyes of 20 patients with
simple MGD (11 women and 9 men; mean age, 63.5  16.5
years; range: 30–99) and 26 right eyes of 26 healthy control
subjects (13 women and 13 men; mean age, 53.2  15.7 years;
range: 32–78) were analyzed. Individually, each confocal
parameter was observed to have acceptable sensitivity and
specificity for the diagnosis of MGD, which appears to be an
important observation. Further studies looking into the sen-
sitivity and specificity of these parameters for the diagnosis
of mild stages of MGD will provide invaluable information.
Moreover, the parameters seemed to correlate well with tear
stability, vital staining scores, tear evaporation rate, and
clinical grading of meibomian gland expressibility and glan-
dular loss.
When the cutoff value of MG acinar unit density (MGAUD) is
set at less than 70 units/mm2, the area under the curve (AUC) is
0.91, and the sensitivity and specificity of the parameter are 81%
and 81%, respectively. The AUC is 1 when the cutoff value of
inflammatory cell density is set at less than 300 cells/mm2; the
sensitivity and specificity of the examination is 100% and 100%,
respectively. The AUCs are 0.93, 0.97 when the cutoff values for
MGLD (MG longest diameter), MGSD (MG shortest diameter) in
the diagnosis of MGD are set at less than 65 and 25 m, respec-
tively. The sensitivity and specificity of these parameters under
these cutoff values are 90% and 81% for MGLD and 86% and 96%
for MGSD, respectively.
It seems that the combination of acinar unit diameter
(MGAUD) with tear stability examination employing 1 L of 1%
fluorescein solution applied with a micropipette or fluorescein
staining results in higher specificity without considerable
change in sensitivity. Combination of MGAUD with tear stabil-
ity or fluorescein vital staining examination also shows a higher
specificity without considerable changes in sensitivity.
APPENDIX 9
Test Identification: Meibometry
Rationale. Casual lid margin oil level can be measured via
meibometry.
Methods and Description
Meibometry was first reported by Chew et al. in 1993308,309 as
a method of indirect assessment of the steady state level of
meibomian lipids at the lid margin (the casual level). In this
Confocal
Parameters304,305
Controls
(n  15 eyes)
MGDs
(n  20 eyes) P
Acinar unit density, per mm2 101.3  33.8 47.6  26.6 0.0001
Acinar unit diameter, m 41.6  11.9 98.2  53.3 0.0001
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Correlation between Confocal Microscopy Parameters, Tear Functions, Meibomian Gland Status
BUT FS RB
MG
Expressibility
Grade
MG Dropout
Grade TEROS
Inflammatory cell density 0.552‡ 0.524‡ 0.479† 0.787‡ 0.781‡ 0.499†
MG acinar unit density 0.557‡ 0.507‡ 0.460† 0.706‡ 0.678‡ 0.530‡
MG acinar shortest diameter 0.408† 0.451† 0.374* 0.731‡ 0.813‡ 0.346*
MG acinar longest diameter 0.342* 0.477‡ 0.308* 0.611‡ 0.723‡ 0.388*
This table was published in Ophthalmology, Vol 117, Ibrahim OM, Matsumoto Y, Dogru M, et al., The efficacy, sensitivity, and specificity of
in vivo laser confocal microscopy in the diagnosis of meibomian gland dysfunction. Page 669, © Elsevier (2010). Reprinted with permission.
BUT  break-up time; FS  fluorescein staining; RB  Rose Bengal staining; TEROS  tear evaporation rate measurements from the ocular
surface.
Spearman’s correlation coefficient by rank test.
* P  0.05, considered significant.
† P  0.005, considered very significant.
‡ P  0.0001, considered extremely significant.
FIGURE 18. This figure was published in Ophthalmology, Vol 117, Ibrahim OM, Matsumoto Y, Dogru M et al., The efficacy, sensitivity, and
specificity of in vivo laser confocal microscopy in the diagnosis of meibomian gland dysfunction. Page 670, ©Elsevier (2010). Reprinted with
permission.
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examination, the meibomian lipids are blotted onto a loop of
plastic tape from the central third of the lower lid margin, and
the amount of lipids taken up is measured optically or scanned
and measured by a computer equipped with commercially
available densitometric software. In the first reports,308,309 it
was shown that the casual lipid level at the lower lid increases
with age, yet is lower in women in their 20s through 60s, and
the lipid level is evaluated as highest in the first hour after
waking, but settles to a constant level throughout the remain-
der of the day. In the original meibometry method, optical
density was read with a clinical meibometer (MB 550; Courage
& Khazaka Electronic GmbH, Cologne, Germany) that obtained
a point reading at the center of the blot. After that, Yokoi et
al.310 reported another method in which the sampled lipid is
scanned and the increase in transparency is integrated over the
length of the blot. A few years later, Komuro et al.311 reported
an originally developed meibometer that included a laser de-
vice comprised of a laser diode (690 nm) and photodetection
units (window size: 2.5  5 mm), and an ultrasonography
probe was used as the mounting area for the plastic tape.311
The latter studies found that the casual lipid level of meibo-
mian gland dysfunction (MGD) is significantly lower than
that in aqueous-deficient dry eyes and normal eyes. The
present limitation of meibometry is that in normal subjects,
the lipid blot is uniform, and results can be extrapolated to
the total lid margin. However, in cases of MGD, focal gland
obstruction may vary along the lid length, so that central
readings may not truly reflect the overall picture. In future
studies, calibrations are needed to convert densitometry
readings into equivalent values for the sampled meibomian
lipid. Furthermore, development of a system to integrate
along the full length of the lid would be ideal, and cutoff
values for the diagnosis of MGD are needed. A detailed
explanation of the examination method is detailed in the
following text.
In the standard technique of meibometry, a preformed loop
of meibometry tape (8 mm wide) is placed in the reading head
of the meibometer, to establish the 0 reading. The loop is
formed by heat-sealing the tape at a predetermined point to
give a loop length of 20 mm. The handle is clipped to the prism
housing of a Goldmann applanation tonometer or an ultra-
sonography probe holder mounted on the slit lamp biomicro-
scope. This arrangement permits controlled placement of the
probe on the lid margin under direct vision. The tonometer or
ultrasonography probe is set at 0 for each impression. With the
subject looking upward without blinking, the lower lid is
gently inverted (stretching should be avoided, as it might
express oil), and the loop is then pressed onto the central third
of the lid margin with sufficient pressure to obtain an imprint
across the entire width of the tape, yet without bending the
handle of the loop. A line of contact is seen across the full
width of the tape, and contact is maintained for 3 seconds.
After the blot is obtained, the tape is kept in the air for 3
minutes, to allow evaporation of any tears picked up from the
lid. The loop is placed in the reading head of the clinical
meibometer, and a reading is taken in the standard way. The
casual lipid level (expressed as arbitrary optical density units)
is calculated as (C  B), where C is the casual reading and B is
the reading from the untouched tape (background). In the pro-
cess of integrated meibometry, the tape loop is opened and
attached to a strip of exposed 35-mm negative film to provide a
black backing. The oil imprint is scannedwith a handheld scanner
into a computer for densitometric analysis. In the process of laser
meibometry, the meibometry is performed with an originally
developed laser device (laser diode with 5 mV and 690 nm in
wavelength and silicon photo diode, window size: 2.5  5 mm)
where the casual lipid level (arbitrary units) is obtained by
(C  B)/A, where A is the reading without tape, B is the reading
before blotting, and C is the reading after blotting.
APPENDIX 10
Test Identification: Interferometry
Rationale. Interferometry utilizes optical principles to vi-
sualize the tear film lipid layer, which consists of the lipid
secreted from the meibomian glands. At the time of eye open-
ing, this lipid layer is repeatedly spread, by blinking, over the
aqueous layer of the tear film.312 The layer is very thin, and
thus the light reflected from the surface and back of the lipid
layer produces interference images that can be observed as
specular images.
Method and Description
Interferometers are instruments that allow visualization and
analysis of the interference image from the lipid layer. Several
types of interferometers have been developed to see the lipid
layer.313–323 Among them, the DR-1 (Kowa) has successfully
been able to give quantitative analysis.317–319,324 Even before
the development of interferometers, the spreading of the lipid
layer over the aqueous layer had been observed. Interferome-
ters provided a clearer image, and thus a difference was no-
ticed in the interference patterns between normal subjects and
dry eyes. Based on these observed differences, grade classifi-
cations were made for precorneal tear film325 and precontact
lens tear film.316,325 For example, for the DR-1 there are five
grades ranging from normal (grade 1 or 2) to dry eye (grades 2
to 5, with a grade of 5 being the most severe).320 Despite the
limitation of this classification system where grade 2 may be
classified either as normal or dry eye, the noninvasive nature of
this test makes it a valuable tool for screening dry eye and
assessing severity. To determine the condition of the lipid
layer, one may measure either the thickness or the spreading
rate of the lipid layer over the ocular surface. Early methods of
measuring the thickness of the lipid layer did not give a precise
value for the thickness, since they relied on Newton’s color
scale which provides a relatively rough and semiquantitative
value.315 However, over time, several advances have been
made in the ability to determine the condition of the lipid layer
by quantitative values. The most sophisticated of these was
developed by a colorimetric approach,317 in which a new tear
interference color chart was developed to describe the thick-
ness of the tear film lipid layer.
A different approach, aimed at assessing kinetically the rate
of spread of the lipid layer over the ocular surface, is based on
two methodologies: One is measuring the spread time of the
lipid layer (the time required to reach a stable lipid film after
opening the eye).318,319 In a study conducted to evaluate tear
lipid spread time and pattern, the lipid spread was found to be
horizontal in healthy eyes but vertical in lipid tear deficiency
(LTD); lipid spread time is greater in normal subjects than in
those with LTD.318 The second methodology measures the
lipid layer spread more directly by using the rheological model,
and it was noticed that the rate of spreading of the lipid layer
depends on the volume of the aqueous layer.320 Based on this
method, one can assess the precorneal aqueous tear volume by
measuring the spread rate of the lipid layer, and normal tear
volume may be given to the higher rate of spreading. Even
though these approaches are still under development, the
techniques have promise in many clinical applications in the
diagnosis and/or quantitative grading of the severity of dry
eye.325
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APPENDIX 11
Test Identification: Evaporimetry
Rationale. Evaporimetry measures tear evaporation from
the ocular surface. The evaporation is very effectively re-
duced by the lipid barrier of the tear film.326 In conditions of
52% humidity at temperatures of 22°C, the evaporation of
water from an open bath is 100  107g/cm2/s.327 When
measured under these conditions, the lipids of the ocular
tear film reduce their evaporation by approximately 80% to
90% in the normal eye. Mishima and Maurice328 in 1961
were the first to establish that the lipid layer retarded evap-
oration in an animal model of the rabbit eye. Iwata et al.329
developed another in vitro rabbit model with a cornea
covered with a chamber through which dry air was passed;
from the weight of water collected, they determined the
evaporative rate to be 10.1  107g/cm2/s. They found that
a fourfold increase in evaporation occurred with the re-
moval of the rabbit’s tear film lipid layer. A similar propor-
tional increase in human tear film evaporation was measured
by Craig and Tomlinson330 in patients with an incomplete or
absent lipid layer, a situation commonly found in MGD. Tear
film evaporation depends on a variety of parameters, includ-
ing ambient air flow and interaction of the numerous com-
ponents in the tear film, including the lipid layer.
Evaporation Rate Derived from Capture of Fluid
Loss from the Ocular Surface
Evaporation of fluid from the ocular tear film has been mea-
sured by numerous investigators since the first report in 1980
by Hamano et al.,331 and a range of different techniques have
been used. Hamano et al.332 determined the evaporation from
the corneal area enclosed in a capsule by a pressure gradient
technique, Cedarstaff et al.333 measured the increase in elec-
trical resistance of air passed over the eye with an increase in
humidity measured with resistance hygrometry. Subsequently,
they adopted the vapor pressure gradient technique, calculat-
ing relative humidity and temperature at two points above an
evaporative surface.334 Others have measured the increases in
humidity of the air in a sealed goggle over time.335–337 Recently
a continuous recording device measured changes in the hu-
midity of the air stream passing over the eye, by microbalance
technology.338
Tear film evaporation rate has been reported in different
units by various researchers,330,334,337,339; most use units of
107g/cm2/s, but others report values in grams per square
meter per hour (g/m2/h). This difference may be resolved and
all values rendered to the same units (107g/cm2/s) by di-
viding the values expressed in grams per square meter per
hour by a factor of 3.6.340 Borchman et al.341 provide an
alternate view in which they have proposed that the evapora-
tion rate be expressed as an equivalent thinning rate of the tear
film in micrometers per minute. These units are simpler and
can be compared directly to measurements of tear thinning
rates.342
Evaporation rates recorded by the measurement of fluid loss
from the ocular surface for normal and dry eyes have been
reported in the literature over the past 30 years (McCann LC, et
al. IOVS 2008;49:ARVO E-Abstract 1542).335–339,343–351 The
rate is also reported in units of microliters per minute by some
researchers.338,339 The evaporation rate in microliters per min-
ute is numerically equal to a hundreth of the value of the
evaporation rate stated in units of 107g/cm2/s, when the area
of the evaporating ocular surface is 167 mm2. The use of
different techniques for measurement of tear film evaporation
makes it difficult to compare evaporative findings in normal
and dry eyes among different studies, because the absolute
values recorded are technique dependent. However, there is a
pattern to the observations reported in the literature, with
significant increases from normal tear film evaporation seen in
patients with both aqueous-deficient dry eye and MGD and
evaporative dry eye (McCann LC, et al. IOVS 2008;49:ARVO
E-Abstract 1542).335,339,344–347,352 Strictly, these comparative
differences within individual studies are of diagnostic signifi-
cance only where values in normal and dry eyes are recorded
by the same technique in the same laboratory. However such
evaluations as meta-analysis of evaporation studies are valid
means of detecting the pattern of differences in normal and dry
eyes; therefore, it is permissible that all values be included in
such an analysis, irrespective of measurement technique.354
Tear film evaporation is raised in both aqueous-deficient dry
eye and evaporative dry eye, compared with normal. In aque-
ous-deficient dry eye, the evaporation rises to an average of
17.91  10.49  107g/cm2/s (from a level in the normal eye
of 13.57  6.52  107g/cm2/s) and is higher still in evapora-
tive dry eye at 25.34  13.80  107g/cm2/s.355
Evaporation measurements are important in the differen-
tial diagnosis of dry eye. Several studies report tear film
evaporation in aqueous-deficient dry eye and MGD or pa-
tients with evaporative dry eye (McCann LC, et al. IOVS
2008;49:ARVO E-Abstract 1542).335,339,344–347,352,353 In
most cases, the evaporation rate is greater in the dry eye
than in the normal eye, as the increased water loss from the
tear film contributes to the dry eye condition. In one study,
almost 90% of the dry eye patients showed lower readings of
tear film evaporation than did normal subjects.345 This dis-
crepancy was explained by considering the relative contri-
bution of tear evaporation to tear dynamics in the dry eye
condition; the proportional loss through evaporation in the
dry eye was greater than in normal eyes, although the actual
water loss (in absolute terms) was decreased compared with
normal values. A reduction in tear fluid volume, however,
would not be reflected in a reduction in evaporation rate
unless the surface area was reduced as well. Although this
could occur if there were very large areas of breakup, it is
unlikely, because a sudden drop in evaporation rate would
occur as the large dry areas develop. A reduced rate of
evaporation can be seen in dry eyes, but is more likely to be
related to a change (increase) in the retardation effect of the
lipid layer. Dry eyes often appear to have a more viscous,
and perhaps thicker, lipid layer than normal.
Evaporation Rate Derived from Measures of Tear
Film Thinning
A new paradigm has recently been introduced into the field of
measurement of human tear film evaporation by King-Smith et
al.342,356–358 who infer rates of evaporation from observations
of tear film thinning. The notion of the actual fluid loss from
the tear film has been thrown into confusion by their recent
suggestion that the primary thinning of the tear film observed
by their imaging interferometer is due to evaporation.356–358
The values for evaporation inferred from tear thinning are of a
different order, a factor of approximately four to five times that
reported in studies of direct measures of the capture of fluid
loss from the ocular surface.355
In a recent meta-analysis, diagnostic cutoff values for evap-
oration rate were found to offer limited sensitivity but better
specificity when normal eyes are compared with all dry eyes
and within each of the dry eye subtypes.355 As a result of the
potential extreme skewing of weighted averages for evapora-
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tion in this meta-analysis, the values obtained from tear thin-
ning measures are not included.
APPENDIX 12
Test Indentification: Tear Lipid Composition and
the Diagnosis of MGD
Rationale. Considerable work has been undertaken in in-
vestigating the composition of tear lipids. The research has
been hindered by the small sample size, difficulty of collection,
the danger of contamination with skin lipids and cosmetics,
storage problems, and intrinsic complexity of the mixture of
the lipids. The analytical techniques used therefore reflect this
complexity. A review of the analysis and composition of hu-
man tear lipids in health and disease will be dealt with in detail
elsewhere in this MGD report.
Methods and Description
Within the current state of knowledge several impediments
hinder the adoption of lipid composition as part of the clinical
diagnosis of MGD. As yet, no uniform method of sample col-
lection has been adopted. Collection techniques have included
meibum from forced expression359 collected with capillar-
ies360 or spatula (Butovich IA, et al. IOVS 2007;48:ARVO E-Ab-
stract 441), lipid extracted from whole tears361 or extracted
from Schirmer strips.362 Once collection is achieved, analysis
of the lipids involves complex multistep analytical techniques
such as FTIR, NMR, GC-MS, TLC-GC-MS, and HPLC-MS.363 Mass
spectroscopy often involves exotic ionization techniques such
as MALDI, ESI, and API. The latest techniques make use of
multistage fragmentation of ions (MSn), which does allow
greater elucidation of structure. These techniques are inher-
ently expensive and time-consuming and require a high level of
expertise. Unfortunately, qualitative information is gained but
quantitative analysis is not readily generated.
Controversy remains regarding the composition of tear lip-
ids in healthy persons, such as the presence359 or absence
(Butovich IA, et al. IOVS 2007;48:ARVO E-Abstract 441) of
phospholipids and ceramides, and reports of high364 and
low361 levels of the fatty acid amide oleamide. Changes in
lipids as a result of disease have been detected in several
studies,360,365–369 but as yet, the changes are not fully under-
stood. It should also be noted that much of the work has been
done in animal models360,366 rather than human subjects.
As each of these issues is addressed, it is anticipated that
lipid analysis will start to play a role in the understanding of
MGD, particularly in a research setting. Considerable further
advances are necessary before lipid analysis can be used as a
diagnostic tool in clinical practice.
APPENDIX 13
Test Identification: Fluorophotometry
Rationale. Tear production, tear turnover, and tear volume
are assessed with fluorophotometry. Several tests have been
devised to measure the rate of disappearance of a dye marker
placed in the tear film with the production of new tears and
through tear elimination from the eye. In most studies, the
disappearance of sodium fluorescein dye from the tear film has
been used to record tear turnover (TTR) by the technique of
fluorophotometry.370–376
Method and Description
Early studies used modified slit lamp fluorophotom-
eters,371,373,377 but the development of a commercial instru-
ment and analysis software376 helped standardize the proce-
dure,372 (i.e., the Fluorotron Master; Coherent Radiation Inc.,
Buffalo, NY). The decay of fluorescein concentration in the
tear film is measured by these techniques over a period of 30
minutes after instillation of 1 L of 2% fluorescein sodium into
the lower fornix with a measuring pipette, with scans being
performed every 2 minutes. The change in rate of decay of
fluorescence is then calculated for the total measurement pe-
riod, and a biphasic decay in fluorescence is observed.372 The
measurements for the first 5 minutes show a rapid decay,
thought to be due to the initial reflex tearing produced by the
instillation of the fluorescein drop. The later part of the curve
(from 5 minutes outward) represents the measurement of tear
turnover under basal conditions of secretion. It is this part of
the curve that is fitted using appropriate software,376 and the
decay in fluorescence is calculated from the log of the curve
obtained from the following formula, to obtain the basal tear
turnover rate:
T0	t0
 
100Ct	t0
 Ct	t0 1

Ct	t0

	%/min)
where Ct(t) is the fluorescein concentration in tear film at
time t(min).
Assuming a monophasic decay of fluorescence from 5 min-
utes after instillation with a decay time constant b (min1)
Ct	t
 Ct	0
  ebt (ng/mL)
the following is obtained:
Tt	t0
  100 (1  ebt) (%/min)
This calculation gives a measurement of the tear turnover
recorded in percentage per minute (%/min). To express the
turnover value in terms of microliters per minute (sometimes
called flow), it is necessary to either assume a value for the tear
volume (typically 7 L377) or to measure the volume from the
initial dilution of the instilled sodium fluorescein in the tears.
Initial dilution is calculated by back extrapolation to time 0 of
the initial fluorescence decay. In this technique, it is the mono-
phasic decay of fluorescence in the first 5 minutes after instil-
lation of the fluorescein that is determined.376,378
Tear volume is derived from the formula377:
Vt 	Cd  Cm 1  k  1  1
Vd
where Cd is the fluorescein concentration in the drop, and Cm
is the initial fluorescein concentration calculated by back ex-
trapolation with the Fluorotron in nanograms per milliliter.
The turnover in microliters per minute is then calculated from
the product of tear turnover in percent per minute and tear
volume. Values have been reported for tear turnover (%/min) and
tear flow (l/min) in major studies in the literature for normal and
dry eye subjects, obtained with a commercial fluorophotom-
eter.375,376,379,380 The data reported for normal subjects in most
studies ranges from 10% to 20%/min, which equates to a tear
flow rate of just over 1 L/min.375–377,379,381–383 In contrast,
Mathers et al.384 found normal tear turnover on the order of
7%/min or 0.19 L/min, values not dissimilar to those found
N vs. DE N vs. EDE ADDE vs. EDE
Cutoff DE  22 EDE  22.3 EDE  27.5
(Sensitivity/specificity) (51.1/89.9) (61.2/90.6) (45.5/79.8)
IOVS, Special Issue 2011, Vol. 52, No. 4 Diagnosis 2037
in dry eyes. It is possible that the values of TTR published by
Mathers are in error, and later reports by this group suggest
a difference in their calculations, producing higher values in
the range of 0.34 to 0.49 L/min.385 TTR in normal subjects
averages 1.03  0.39 L/min (16.19%  5.10%/min) when
Mathers’ values are excluded and for the dry eye in all its
forms, the average is 0.54  0.28 L/min (9.26%  5.08%/
min). In those cases subtyped as aqueous-deficiency dry eye,
the mean TTR is 0.40  0.1 L/min (7.71%  1.02%/min)
and in evaporative dry eye, the mean is 0.71  0.25 L/min
(11.95  4.25%/min). These results suggest that all dry eyes
show a reduced production facility (TTR) relative to the nor-
mal by approximately 60% in aqueous-deficient dry eye and by
30% in evaporative dry eye. Diagnostic cutoffs for TTR offer
promising sensitivity and specificity when normal eyes were
compared with all dry eyes and with each of the dry eye
subtypes in a recent meta-analysis.386 TTR has potential in
differentiating both evaporative dry eye (resulting from MGD)
from the normal, as well as from aqueous-deficient dry eye,
being a sensitive measure in the former case and highly specific
in the latter (i.e.; efficient in classifying evaporative dry eye).
Tear Volume by Fluorophotometry: Reported
Values
Measurement of tear volume by the fluorometric technique has
yielded little difference between the volume in normal or dry
eyes (including MGD).379,380 This outcome is unlike the situa-
tion with measurement by meniscometry where differences
have been found. Scherz et al.383 have also found correlations
between tear meniscus height (TMH) and volume by fluoro-
photometry. Volume measures by fluorophotometry were not
found to correlate with PRT by Tomlinson et al.386
APPENDIX 14
Test Identification: Meniscometry
Rationale. Meniscometry provides a measure of tear me-
niscus height, radius, and volume.
Methods and Description
There are many ways to evaluate tear meniscus parameters,
such as measuring the height, radius, width, and cross-sec-
tional area, because 75% to 90% of total tear volume of the
ocular surface is estimated to be kept in the tear meniscus.387
Among those parameters, measurement of tear meniscus
height is the most popular assessment method, and there have
been numerous reports that have attempted to use meniscus
height in the diagnosis of tear deficiency. However, those
previous methods require fluorescein instillation to obtain
clear visualization, and this may induce reflex tearing due to
some invasiveness. Yet in a report on slit-image photogra-
phy388 that compared tear meniscus parameters, including
height, radius, width, and cross-sectional area, the height and
radius of the meniscus were found to be the best parameters
for the diagnosis of dry eye.388 That method did employ fluo-
rescein instillation, however, thus introducing some invasive-
ness that may cause reflex tearing and may add some aqueous
to the original tear volume. Based on that background, menis-
cometry was developed.389,390 Today, there are two systems of
meniscometry; one based on photography390 and one based on
the use of video.391 In a newly developed video-meniscometer,
a rotatable projection system with a target comprising a series
of black and white stripes (four black and five white; each 4
mm wide) was introduced coaxially, using a half-silvered mir-
ror. The coaxial alignment of the video-meniscometer permits
the meniscus of either eye to be readily accessed and allows for
real-time recording of meniscus behavior corresponding to a
1.1  1.5 mm rectangular area of the meniscus. For the pur-
pose of calculating the radius of tear meniscus curvature, a
selected meniscus image recorded on a digital video recorder is
captured on the computer, and analyzing software is applied
for the calculation of the radius according to the concave
mirror formula:
R  2W	I/T

where R is the radius of the tear meniscus, W is the working
distance, I is the image size, and T is the target size.
Using meniscometry, the R values in normal eyes were
calculated as 0.365  0.153 mm (n  36) by the photographic
system. However, probably due to some invasiveness of the pho-
tographic system as it sought the image in a dim light, the calcu-
lated R values were larger than those obtained by the video
system391 (0.30 0.10 mm, n  36), but smaller than those
obtained by slit-image photography (0.55 0.26, n  15).388
Those differences are due to the effect of reflex tearing or the
instillation of fluorescein into the aqueous. In a recent advance-
ment in optical coherence tomography (OCT), the R values are
reportedly the smallest yet obtained (0.239 0.112 mm n 
40).393 It has also been reported that those normal R values
were smaller than those in dry eyes (0.17  0.05 mm,393 n 
38; 0.22  0.09 mm,394 n  29).
Through research using a video-meniscometer, the radius of
the tear meniscus at the central lower lid margin of the left eye
was measured in 36 healthy volunteers, 38 dry eye subjects
(diagnoses based on the Japanese dry eye criteria), and seven
dry eye patients with punctal plugs in both upper and lower
puncta. Among those groups, the respective tear meniscus
radii (R, in millimeters) were compared. The results showed a
significantly smaller meniscus in dry eyes (R  0.17  0.05
[SD]) compared with that in normal eyes (0.30  0.11 mm;
P 0.0001), whereas a significantly larger meniscus was found
in dry eye patients with punctal plugs (0.57  0.23) than in
normal eyes (P  0.0001) or dry eyes (P  0.0001).393 Four-
teen subjects from the normal group and 31 patients from the
dry eye group had undergone the Schirmer 1 test, so the
correlation between the radii and values of the Schirmer I test
was investigated in those groups. It was found that there was
an excellent agreement between the radius of tear meniscus
and the Schirmer 1 test. If normal is determined by the fact that
both the tear and ocular surface examinations are normal and
the cutoff value of the radius is determined as 0.25 mm, then
the sensitivity and specificity for the radius were calculated as
88.9% and 77.8%, respectively, which is compatible with the
measurement of meniscus height.395
Considering that the radius measurement obtained by me-
niscometry is noninvasive and that there is a significantly good
correlation between R and total tear volume over the ocular
surface,396 the tear meniscus may be the expectable parameter
for the screening of tear deficiency. For other applications, the
video-meniscometer enables real-time monitoring of tear vol-
ume and also allows tear turnover to be evaluated after the
instillation of eye drops, where not only the turnover of tear
substitute at the ocular surface is evaluated but also the efficacy
of drainage of the lacrimal pathway.
N vs. DE N vs. EDE ADDE vs. EDE
Cutoff DE  12.9 EDE  15.1 ADDE  9.6
(Sensitivity/
specificity) (74.5/73.6) (80.2/58.7) (69.5/96.8)
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APPENDIX 15
Test Identification: Osmolarity
Rationale. Tear film osmolarity indicates the balance of
inputs and outputs of the lacrimal system.
Methods and Description
The osmolarity of a sample can be determined in several ways,
both in situ and by sampling, using methods that measure the
colligative properties of the tears. These properties, such as
freezing-point depression and vapor pressure, depend on the
number of dissolved particles in a solution but are not depen-
dent on the identity of the particles. The freezing point depres-
sion nanoliter osmometer is at present the most commonly
applied principle in osmolarity measurement.397,398 In this
method, the temperature of the freezing point is directly pro-
portional to the total number of dissolved particles in the
solution. Therefore, the osmolarity can be calculated from the
depression in the freezing point. The most frequently applied
freezing point depression techniques in tear research use nano-
litre samples,398–402 most commonly with the Clifton Nanoli-
tre Osmometer (Clifton Technical Physics, Hartford, NY).400
Although used in the diagnosis of dry eye disease, this method
requires significant expertise, takes considerable time, and is
open to error due to evaporation of test samples.401 Other
techniques using the freezing-point depression technique such
as the Advanced Tear Osmometer (Advanced Instruments, Inc.,
Norwood, MA) and the Otago Osmometer (Otago Osmometers
Ltd, Dunedin, New Zealand) are also available.
Vapor pressure techniques have also been used in the mea-
surement of osmolarity.402 These work on the principle that the
vapor pressure of a solution is lower than that of the pure solvent
at the same temperature and pressure; the decrease in vapor
pressure, like depression of freezing point is proportional to the
number of dissolved particles in the solution. Thus, the osmolarity
of a solute can be calculated from its vapor pressure. Original
vapor pressure osmometers engaged a precision thermocouple
hygrometer to measure dew point depression and required large
sample volumes.402 This necessitated the collection of reflex tears
which in turn could lower the osmolarity values obtained.403
More recently, vapor pressure osmometers, such as the Wescor
(Wescor, Inc., Logan UT) have been used. However, although
easier to operate and more streamlined than freezing-point de-
pression osmometers, they are still not suitable for the quick, easy
application required in clinical practice.
There is a need for a new instrument to facilitate clinical
application and the adoption of osmolarity as a diagnostic
test in dry eye disease. Recently the OcuSense system
(OcuSense Inc., San Diego, CA) has been developed.400,404
This new osmometer is based on electrical impedance and
“laboratory-on-a-chip” technology, which allows the calcu-
lation of osmolarity. This technique allows osmolarity test-
ing of a very small volume (less than 20 nL), is a quick and
accurate measurement of the osmolarity of the tear film in a
clinical setting, and reduces the evaporation of the fluid.
However, although the device measures charged particles,
corrections or assumptions are made with regard to the
contribution made by noncharged particles in the tear sam-
ple. The OcuSense system has recently been approved as a
medical device by U.S. Food and Drug Administration. A
recent study compared the new OcuSense osmometer with
the Clifton Osmometer, to determine the comparability of
results between the instruments. Osmolarity values for con-
trols and dry eye were 308  6 mOsm/L and 321  16
mOsm/L, respectively (OcuSense) and 310  7 mOsm/L and
323  14 mOsm/L respectively (Clifton); the difference was
signnificant. Significant correlation was found between
OcuSense and Clifton measurements (r  0.904; P  0.006).
Bland-Altman analysis revealed agreement between tech-
niques; most of the points fell within the 95% confidence
limits, and actual values differed by less than 1%.404
A previous meta-analysis was performed on published data
for tear osmolarity in samples of normal subjects and various
subtypes of dry eye and pooled estimates of the mean and
standard deviations for normal and (all) dry eye subjects were
determined.405 A diagnostic referent (cutoff) value was derived
and tested for effectiveness of diagnosis on independent
groups of normal and dry eye subjects. A referent value of
315.6 mOsm/L was derived from the intercept of the distribu-
tion curves, and 316 mOsm/L from the ROC curve. When
applied to independent groups of normal and (all) dry eye
subjects, a value of 316 mOsm/L was found to yield sensitivity
of 59%, specificity of 94%, and overall predictive accuracy of
89% for the diagnosis of dry eye syndrome. Tear hyperosmolar-
ity, defined by a referent value of 316 mOsm/L, was superior in
overall accuracy to any other single test for dry eye diagnosis.
Osmolarity is use in differentiating evaporative dry eye from
the normal, but is of limited ability in assigning the subtypes
into categories of aqueous-deficient dry eye and evaporative
dry eye; this outcome is not unexpected when osmolarity in
the subtypes is reported as 330.01  13.34 and 325.57 
14.76, respectively, and 308.39  9.29 in the normal in a
recent study.406 Utilization of easy-to-operate instrumentation
with high levels of sensitivity alone or in addition to dry eye
clinical testing will continue to provide valuable information
about the fundamental underpinnings of osmolarity as it relates
to ocular surface disease.407
APPENDIX 16
Test Identification: Indices of Tear Film Dynamics
Rationale. It would be useful in the study of dry eye to be
able to describe and quantify tear film dynamics–-the balance
of inputs and outputs–-of the lacrimal system (the combination
N vs. DE N vs. DE N vs. DE
Technique Meniscometry393 Farrell et al.395 Small vol. fluorescein388
Cutoff, mm DE  0.25 DE  0.18  9.6
(Sensitivity/specificity) (74.5/73.6) (72.8/66.6) (93.3/66.7)
N vs. DE408 N vs. EDE406 ADDE vs. EDE406
TFI Cutoff, mOsm/L DE  316 EDE  315 ADDE  325
(Sensitivity/specificity) (69%/92.8%) (73%/72%) (60%/39%)
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of production and evaporative loss) by a single index that
describes the balance of input and output of the system.409
Methods and Description
Tear Function Index. An early index for tear film dynam-
ics was the Tear Function Index (TFI) devised by Xu et al.410
This index combined values obtained for tear secretion (from
the Schirmer test with anesthesia) with measurements for
drainage (turnover as measured by the fluorescein clearance
test411) in the following formula:
TFI 
Schirmer value with anesthesia410,412
Tear clearance rate
This index includes measures of two of the three main factors
that determine tear dynamics410: secretion and drainage. It has
been argued that tear secretion is the most important determi-
nant of tear dynamics,410 but, as it could not be measured
independently and directly, the Schirmer test result had to
represent the production component of dynamics.410 The abil-
ity of the TFI to discriminate between normal and dry eye
patients was found to be considerably better than the Schirmer
test or the tear clearance rate values alone. A value of the log
to the base 2 of the TFI below 96 gave a sensitivity and
specificity in the diagnosis of dry eye of 67.4% and 60%,
respectively. A value for TFI below 34, gave sensitivity and
specificity calculations for Sjo¨gren syndrome of 78.9% and
91.8%411 The major deficiency of the TFI as an index of tear
dynamics is that it fails to take into account the elimination of
tear fluid from the eye through evaporation. Evaporation is a
key variable in differentiating some groups of dry eye.413 A
recent study determined the effectiveness in dry eye diagnosis
of another Tear Function Index (the Liverpool modification of
the TFI) test.414 This report showed high sensitivity at 83% in
the diagnosis of all dry eye from the normal but poor specificity
(40%).
Total Tear Flow
Ideally, any index of tear dynamics should define the imbalance
that leads to the condition of dry eye. Under basal conditions,
the majority of the input, and output, of the lacrimal system
can be determined through measurement of tear turnover and
fluid loss by evaporation.409 Mathers415 has suggested “total
tear flow” as an index that captures the principal sources of
elimination of tear fluid from the eye. As the drainage facility is
not necessarily affected in dry eye states,416 the tear flow is
determined from tear turnover rate (effectively a measure of
drainage) and, combined with evaporation, it gives an estima-
tion of the tear production facility of the eye.415 Therefore, dry
eye may result when tear flow (turnover) is reduced due to a
deficiency of tear production deficiency (aqueous-deficient dry
eye) or a high level of evaporation occurs (evaporative dry eye)
in MGD or blepharitis. Mathers suggests that in the assessment
of the balance of production and outflow from the eye, the
proportion of elimination due to evaporation as a part of the
total tear flow is essential. Tomlinson et al.,417 in a meta-
analysis, analyzed the values for tear turnover and evaporation
rates and the total tear flow from the literature (including
Mathers’ publications,413,415,418 even though the values re-
corded for tear turnover by Mathers et al. in some re-
ports417,418 are considerably below those recorded by others
and may be in error). Mathers415,419 has reported that approx-
imately one third of the resting tear flow evaporates in the
normal eye. This increases to 75% of the total tear flow in the
dry eye,415 although the total tear flow in normal subjects and
dry eye patients recorded by Mathers is similar, at around 0.5
L/min. In a later paper, Mathers418 observed the percentage
loss of tear fluid from the eye through evaporation to be
approximately 55% in dry eyes.
The value for the comparison of evaporative loss to total
tear flow (evaporationTTR) in the meta-analysis417 indicates
that the proportion of loss is about one eighth or 12% in the
normal (14.4% if Mathers’ data are included). In dry eye of all
types, this increses to over a quarter or 28%. It is similar in both
the dry eye subtypes, being 28.3% in aqueous-deficient dry eye
and 26.8% in evaporative dry eye.
Evaporation and Tear Turnover
A similar but simpler index is derived from the proportion of
the production, measured by tear turnover rate (TTR), lost
through evaporation.417 For these analyses, TTR can be
thought of as a measure of production, although TTR may also
be considered a measure of drainage. A meta-analysis (with and
without Mathers’ values for TTR) show that for this simple
ratio, close to one eighth (13.6%) of the tear production (TTR)
is lost through evaporation in the normal eye. In (all) dry eye
the level of evaporative loss rises to 38.9%. In the subtypes of
dry eye, the evaporative loss for aqueous-deficient dry eye is
39.5% of TTR and for evaporative dry eye, the loss is similar, at
36.6% of the TTR.
The use of indices derived from evaporation and TTR mea-
sures, whether combined into “total tear flow” as a denomina-
tor414 or using a single turnover measure for production,
makes little difference in the ability to distinguish dry eye states
from the norm. In fact, the difference with the simpler index of
evaporation/TTR is slightly larger than for evaporation/total
tear flow index; 2.7 to 2.9 times compared with 2.2 to 2.4.
Both indices show that dry eye, in all its forms, has a greater
loss of fluid by evaporation, compared with its production,
than occurs in the normal eye. The dynamic imbalance of loss
to production is slightly greater in aqueous-deficient dry eye
than in evaporative dry eye, even though the eye with evapo-
rative dry eye has a greater loss through evaporation. The
combined, though moderate, increase in evaporation in the
N vs. DE411 N vs. DE414 N vs. EDE414 ADDE vs. EDE414
TFI Cutoff DE  96 DE  240 EDE, NA EDE, NA
(Sensitivity/specificity) (64.7/60) (83%/40%) (NA) (NA)
N vs. DE417 N vs. EDE417 ADDE vs. EDE417
Ratio of Evaporation/Total Tear Flow
Cutoff DE  15 EDE  15 EDE, NA
(Sensitivity/specificity) (NA) (NA) (NA)
Ratio of Evaporation/TTR
Cutoff DE  20 EDE  20 EDE, NA
(Sensitivity/specificity) (NA) (NA) (NA)
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eye with aqueous-deficient dry eye, and the poorer production
facility (approximately half that of evaporative dry eye) ac-
counts for the greater imbalance in the eye with aqueous-
deficient dry eye.417 It appears that a change in the balance
between input (TTR) and output (evaporation) by a factor of
more than two or three times (dependent on index) leads to
dry eye. So that the output:input percentage changes from just
over 12% in the normal to greater than 25% in dry eye states
(26.8% in evaporative dry eye and 28.3% in aqueous-deficient
dry eye with the total tear flow index; or 36.6% in evaporative
dry eye and 39.5% in aqueous-deficient dry eye from the simple
index).
The above analysis is based on considering one input to the
tear film from the lacrimal gland, and two outputs: drainage
and evaporation. Levin and Verkman,420 have emphasized the
importance of a second input–-osmotic flow from the conjunc-
tiva and cornea into the hyperosmolar tears. This osmotic flow
helps to reduce the osmolarity increase caused by evaporation
and could help to explain why the high evaporation rates
proposed by King-Smith et al.421 may not necessarily lead to
unreasonably high osmolarity.
APPENDIX 17
The following are the diagnostic criteria for obstructive MGD
proposed by the Japanese MGD Working Group.
Obstructive Meibomian gland dysfunction is considered to
be present when all of the following three signs/findings are
present:
1. Chronic ocular discomfort.
2. Anatomic abnormalities around the meibomian gland ori-
fices (presence of one or more of the following is positive).
a. Vascular engorgement.
b. Anterior or posterior displacement of the MCJ.
c. Irregularity of the lid margin.
3. Obstruction of the meibomian glands (presence of both is
considered positive).
a. Obstructive findings of the gland orifices by slit lamp
biomicroscopy (pouting, plugging, or ridge).
b. Decreased meibum expression by moderate digital pres-
sure.
These diagnostic criteria for obstructive MGD were pub-
lished in Atarashii Ganka (Journal of the Eye) 2010;27:627–
631, and are reprinted in this appendix with the permission
from the publisher (Medical-Aoi Publications Inc.).
The Japanese MGD Working Group consists of the follow-
ing members:
Shiro Amano, Reiko Arita (University of Tokyo), Shigeru
Kinoshita, Norihiko Yokoi, Chie Sotozono, Aoi Komuro, Tomo
Suzuki (Kyoto Prefectural University of Medecine), Jun
Shimazaki, Seika Den (Tokyo Dental College), Kohji Nishida,
Naoyuki Maeda, Shizuka Ko (Osaka University), Yukichi Hori
(Toho University), Hisayo Kubota (Tohoku University), Eiki
Goto (Tsurumi University), Masahiko Yamaguchi (Ehime Uni-
versity), Hiroto Obata (Jichi Medical University), Masakazu
Yamada (Tokyo Medical Center), Dogru Murat, Yoko Ogawa,
Yukihiro Matsumoto, Kazuo Tsubota (Keio University).
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